View Filing Data

Cover - USD ($)	12 Months Ended
Cover - USD ($)	Dec. 31, 2019	Mar. 20, 2020	Jun. 28, 2019
Cover page.
Entity Registrant Name	YIELD10 BIOSCIENCE, INC.
Entity Central Index Key	0001121702
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		1,923,184
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Public Float			$ 8,012,418

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 5,417	$ 3,023
Short-term investments	5,700	2,746
Accounts receivable	72	94
Unbilled receivables	20	66
Prepaid expenses and other current assets	475	448
Total current assets	11,684	6,377
Restricted cash	332	332
Property and equipment, net	1,243	1,385
Right-of-use assets	3,141	4,766
Other assets	318	100
Total assets	16,718	12,960
Current Liabilities:
Accounts payable	279	117
Accrued expenses	1,326	680
Lease liabilities	602	844
Total current liabilities	2,207	1,641
Lease liabilities, net of current portion	3,619	5,621
Warrant liability (Note 9)	14,977	0
Total liabilities	20,803	7,262
Commitments and contingencies (Note 7)
Series B Convertible Preferred Stock ($0.01 par value per share); 5,750 and 0 shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively (Note 9)	0	0
Stockholders' (Deficit) Equity:
Series A Convertible Preferred Stock ($0.01 par value per share); 796 and 0 shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively	0	0
Common stock ($0.01 par value per share); 60,000,000 shares authorized at December 31, 2019 and 2018, respectively, and 933,423 and 250,631 shares issued and outstanding at December 31, 2019 and 2018, respectively	9	3
Additional paid-in capital	360,926	357,743
Accumulated other comprehensive loss	(126)	(110)
Accumulated deficit	(364,894)	(351,938)
Total stockholders' (deficit) equity	(4,085)	5,698
Total liabilities, convertible preferred stock and stockholders' (deficit) equity	$ 16,718	$ 12,960

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Series B Convertible Preferred Stock, par value per share (in dollars per share)	$ 0.01	$ 0.01
Series B Convertible Preferred Stock, shares issued (in shares)	5,750	0
Series B Convertible Preferred Stock, shares outstanding (in shares)	5,750	0
Preferred stock, par value per share (in dollars per share)	$ 0.01
Common stock, par value per share (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	60,000,000	60,000,000
Common stock, shares issued	933,423	250,631
Common stock, shares outstanding	933,423	250,631
Series A Convertible Preferred Stock
Preferred stock, par value per share (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares issued	796	0
Preferred stock, shares outstanding	796	0

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenue:
Total revenue	$ 806	$ 556
Expenses:
Research and development	4,848	4,783
General and administrative	4,554	5,092
Total expenses	9,402	9,875
Loss from operations	(8,596)	(9,319)
Other income (expense):
Loss on issuance of securities (Note 9)	(13,018)	0
Offering costs (Note 9)	(1,254)	0
Change in fair value of warrants (Note 9)	9,541	0
Interest income	96	158
Other income (expense), net	21	(24)
Total other income (expense)	(4,614)	134
Net loss from operations before income tax benefit	(13,210)	(9,185)
Income tax benefit	(254)	0
Net loss	$ (12,956)	$ (9,185)
Basic and Diluted net loss per share (in dollars per share)	$ (35.50)	$ (36.99)
Number of shares used in per share calculations:
Basic and Diluted (in shares)	364,967	248,312
Grant revenue
Revenue:
Total revenue	$ 806	$ 556

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Statement of Comprehensive Income [Abstract]
Net loss	$ (12,956)	$ (9,185)
Other comprehensive income (loss):
Change in foreign currency translation adjustment	(16)	(25)
Total other comprehensive loss	(16)	(25)
Comprehensive loss	$ (12,972)	$ (9,210)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities
Net loss	$ (12,956)	$ (9,185)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	203	196
Loss on issuance of securities	13,018	0
Change in fair value of warrants	(9,541)	0
Expense for 401(k) company common stock match	98	102
Stock-based compensation	656	1,181
Noncash lease expense	1,625	588
Deferred tax provision	(254)	0
Changes in operating assets and liabilities:
Accounts receivable	22	(40)
Unbilled receivables	46	(1)
Prepaid expenses and other assets	9	(128)
Accounts payable	162	41
Accrued expenses	502	(1,072)
Lease liabilities	(2,244)	(436)
Net cash used in operating activities	(8,654)	(8,754)
Cash flows from investing activities
Purchase of property and equipment	(61)	(42)
Purchase of investments	(5,704)	(11,496)
Proceeds from sale and maturity of short-term investments	2,750	8,750
Net cash used by investing activities	(3,015)	(2,788)
Cash flows from financing activities
Proceeds from warrants exercised	0	124
Proceeds from securities offerings, net of issuance costs	14,083	0
Taxes paid on employees' behalf related to vesting of stock awards	(4)	(6)
Net cash provided by financing activities	14,079	118
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(16)	(25)
Net increase (decrease) in cash, cash equivalents and restricted cash	2,394	(11,449)
Cash, cash equivalents and restricted cash at beginning of period	3,355	14,804
Cash, cash equivalents and restricted cash at end of period	5,749	3,355
Supplemental Cash Flow Disclosure:
Interest paid	7	19
Supplemental Disclosure of Non-cash Information:
Right-of-use assets acquired in exchange for lease liabilities	$ 0	$ 194

CONSOLIDATED STATEMENTS OF SERIES B CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	Series B Warrants	Preferred Stock	Common Stock	Common Stock Series B Warrants	Additional Paid-In Capital	Additional Paid-In Capital Series B Warrants	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Registered direct offering	Registered direct offering Common Stock	Registered direct offering Additional Paid-In Capital	Public offering Common Stock	Public offering Additional Paid-In Capital	Series A Convertible Preferred Stock Preferred Stock	Series A Convertible Preferred Stock Public offering Preferred Stock
Balance at Dec. 31, 2017	$ 13,502			$ 2		$ 355,520		$ (85)	$ (342,753)						$ 818
Balance (in shares) at Dec. 31, 2017				227,219											1,826
Increase (decrease) in stockholders' equity
Non-cash stock-based compensation expense	1,181					1,181
Issuance of common stock for 401(k) match	$ 107					107
Issuance of common stock for 401k match (in shares)	1,638			1,638
Issuance of stock for restricted stock unit vesting, net of shares withheld for employee taxes	$ (6)					(6)
Issuance of stock for restricted stock unit vesting, net of shares withheld for employee taxes (in shares)				110
Issuance of stock	0	$ 124		$ 1	$ 0	817	$ 124
Issuance of stock (in shares)				20,287	1,377
Issuance of common stock upon conversion of Series A Convertible Preferred Stock															$ (818)
Issuance of common stock upon conversion of Series A Convertible Preferred Stock (in shares)															(1,826)
Effect of foreign currency translation	(25)							(25)
Net loss	(9,185)								(9,185)
Balance at Dec. 31, 2018	5,698		$ 0	$ 3		357,743		(110)	(351,938)
Balance (in shares) at Dec. 31, 2018			0	250,631
Series B Convertible Preferred Stock, balance at Dec. 31, 2017	$ 0
Series B Convertible Preferred Stock, balance (in shares) at Dec. 31, 2017	0
Series B Convertible Preferred Stock, balance at Dec. 31, 2018	$ 0
Series B Convertible Preferred Stock, balance (in shares) at Dec. 31, 2018	0
Increase (decrease) in stockholders' equity
Non-cash stock-based compensation expense	$ 521					521
Issuance of common stock for 401(k) match	$ 89					89
Issuance of common stock for 401k match (in shares)	2,885			2,885
Issuance of stock for restricted stock unit vesting, net of shares withheld for employee taxes	$ (4)					(4)
Issuance of stock for restricted stock unit vesting, net of shares withheld for employee taxes (in shares)				116
Issuance of stock	0			$ 2		(2)				$ 2,583		$ 2,583	$ 4	$ (4)
Issuance of stock (in shares)				213,500	1,378						60,541		405,750			2,504
Issuance of common stock upon conversion of Series A Convertible Preferred Stock															$ 0
Issuance of common stock upon conversion of Series A Convertible Preferred Stock (in shares)															(1,708)
Effect of foreign currency translation	(16)							(16)
Net loss	(12,956)								(12,956)
Balance at Dec. 31, 2019	(4,085)			$ 9		$ 360,926		$ (126)	$ (364,894)						$ 0
Balance (in shares) at Dec. 31, 2019				933,423											796
Increase (Decrease) in Temporary Equity
Issuance of preferred stock in connection with private offering	$ 0
Issuance of preferred stock in connection with private offering (in shares)	5,750
Series B Convertible Preferred Stock, balance at Dec. 31, 2019	$ 0
Series B Convertible Preferred Stock, balance (in shares) at Dec. 31, 2019	5,750

CONSOLIDATED STATEMENTS OF SERIES B CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Stock withheld for employee taxes (in shares)	55	65
Registered direct offering
Offering costs	$ 349

Nature of Business and Basis of Presentation	12 Months Ended
Nature of Business and Basis of Presentation	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business and Basis of Presentation	Nature of Business and Basis of Presentation Yield10 Bioscience, Inc. is an agricultural bioscience company that uses its "Trait Factory" and the Camelina oilseed “Fast Field Testing” system to develop high value seed traits for the agriculture and food industries. The Company's goal is to efficiently develop superior gene traits for the major crops including corn, soybean, canola, and other crops to enable step-change increases in crop yield of at least 10-20 percent. The “Trait Factory” encompasses discovery of gene targets using the GRAIN (“Gene Ranking Artificial Intelligence Network”) big data mining platform, deployment of trait gene targets in the oilseed Camelina and generation of field performance data. The “Trait Factory” enables two complementary commercial opportunities with different paths to market. The first is trait licensing to the major seed companies for corn, soybean, canola and other crops. Data from the Company's trait field testing in Camelina has enabled Yield10 to establish research license agreements with leading seed companies including Bayer, Forage Genetics and Simplot. These companies are progressing the development of Yield10 traits in soybean, forage sorghum, and potato, respectively. The second is to improve the performance and value of Camelina as a platform to develop a commercial crop product business producing nutritional oils and PHA biomaterials. Using this approach, Yield10 can leverage the resources of the major seed companies to efficiently develop superior gene traits for the major crops and focus internal resources on trait gene discovery and the commercial development of Camelina products. The accompanying consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. With the exception of a single year, the Company has recorded losses since its initial founding, including its fiscal year ending December 31, 2019. During the year ended December 31, 2019, the Company was successful in raising adequate capital to fund its operations, ending the year with unrestricted cash, cash equivalents and short-term investments of $11,117. In March 2019, the Company closed on a registered direct offering of its common stock, raising $2,582, net of offering costs, and in November 2019, the Company closed on concurrent public and private offerings of its securities, raising an additional $10,246, net of offering costs. Through March 20, 2020, Yield10 received a further $1,638 million in cash from the exercise of 204,796 investor warrants issued in the November 2019 offering. The Company follows the guidance of Accounting Standards Codification ("ASC") Topic 205-40, Presentation of Financial Statements-Going Concern, in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year after the date its financial statements are issued. The Company's ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing through, among other sources, public or private equity financing, secured or unsecured debt financing, equity or debt bridge financing, warrant holders' ability and willingness to exercise the Company's outstanding warrants, additional government grants or collaborative arrangements with third parties, as to which no assurance can be given. Management does not know whether additional financing will be available on terms favorable or acceptable to the Company when needed, if at all. if adequate additional funds are not available when required, management will be forced to curtail the Company's research efforts, explore strategic alternatives and/or wind down its operations and pursue options for liquidating its remaining assets, including intellectual property and equipment. Based on its current cash forecast, including funds received after year-end from the exercise of warrants, management has determined that the Company's present capital resources will be sufficient to fund its planned operations into the second quarter of 2021. This forecast of cash resource is forward-looking information that involves risks and uncertainties, and the actual amount of expenses could vary materially and adversely as a result of a number of factors. If the Company issues equity or debt securities to raise additional funds, (i) the Company may incur fees associated with such issuance, (ii) its existing stockholders may experience dilution from the issuance of new equity securities, (iii) the Company may incur ongoing interest expense and be required to grant a security interest in Company assets in connection with any debt issuance, and (iv) the new equity or debt securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. In addition, utilization of the Company’s net operating loss and research and development credit carryforwards may be subject to significant annual limitations under Section 382 of the Internal Revenue Code of 1986, as amended, (the "Internal Revenue Code") due to ownership changes resulting from equity financing transactions. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products or proprietary technologies or grant licenses on terms that are not favorable to the Company.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB Accounting Standards Codification (ASC).

Principles of Consolidation

The Company's consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions were eliminated, including transactions with its Canadian subsidiary, Metabolix Oilseeds, Inc.

Reverse Stock Split

On January 15, 2020, the Company effected a 1-for-40 reverse stock split of its common stock. Unless otherwise indicated, all share amounts, per share data, share prices, and conversion rates set forth in these notes and the accompanying financial statements have, where applicable, been adjusted retroactively to reflect this reverse stock split.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid investments purchased with an original maturity date of ninety days or less at the date of purchase to be cash equivalents.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's condensed consolidated balance sheets included herein:



	December 31, 2019		December 31, 2018
Cash and cash equivalents	$	5,417	$	3,023
Restricted cash	332		332
Total cash, cash equivalents and restricted cash	$	5,749	$	3,355

Amounts included in restricted cash represent those required to be set aside by contractual agreement. Restricted cash of $332 at December 31, 2019 and December 31, 2018 primarily consists of funds held in connection with the Company's lease agreement for its Woburn, Massachusetts facility.

Investments

Short-term investments represent holdings of available-for-sale marketable debt securities in accordance with the Company's investment policy. The Company considers all investments purchased with an original maturity date of ninety days or more at the date of purchase and a maturity date of one year or less at the balance sheet date to be short-term investments. All other investments are classified as long-term. The Company held no long-term investments at December 31, 2019 and December 31, 2018.

Investments in marketable debt securities are recorded at fair value, with any unrealized gains and losses reported within accumulated other comprehensive income as a separate component of stockholders' (deficit) equity until realized or until a determination is made that an other-than-temporary decline in market value has occurred. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion together with interest on securities are included in interest income on the Company's consolidated statements of operations. The cost of marketable securities sold is determined based on the specific identification method and any realized gains or losses on the sale of investments are reflected as a component of other income (expense).

Foreign Currency Translation

Foreign denominated assets and liabilities of the Company's wholly-owned foreign subsidiaries are translated into U.S. dollars at the prevailing exchange rates in effect on the balance sheet date. Revenues and expenses are translated at average exchange rates prevailing during the period. Any resulting translation gains or losses are recorded in accumulated other comprehensive income (loss) in the consolidated balance sheet. When the Company dissolves, sells or substantially sells all of the assets of a consolidated foreign subsidiary, the cumulative translation gain or loss of that subsidiary is released from comprehensive income (loss) and included within its consolidated statement of operations during the fiscal period when the dissolution or sale occurs.

Comprehensive Income (Loss)

Comprehensive income (loss) is comprised of net income (loss) and certain changes in stockholders' equity that are excluded from net income (loss). The Company includes unrealized gains and losses on debt securities and foreign currency translation adjustments in other comprehensive income (loss).

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents, short-term investments and accounts receivable. The Company has historically invested its cash equivalents in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes. Investments are acquired in accordance with the Company's investment policy which establishes a concentration limit per issuer.

The Company's receivables related to government grants are believed to have a low risk of default. At December 31, 2019, the Company's accounts and unbilled receivables of $92 include $62 due from research grants with the U.S. government under which the Company serves as a subcontractor. At December 31, 2018, all of the Company's accounts and unbilled receivables of $160 were from grants with the U.S. government.

Fair Value Measurements

The carrying amounts of the Company's financial instruments as of December 31, 2019 and December 31, 2018, which include cash equivalents, accounts receivable, unbilled receivables, accounts payable, and accrued expenses, approximate their fair values due to the short-term nature of these instruments. See Note 4 for further discussion on fair value measurements.

Segment Information

The accounting guidance for segment reporting establishes standards for reporting information on operating segments in annual financial statements. The Company is an agricultural bioscience company operating in one segment, which is the development of new technologies to enable step-change increases in crop yield to enhance global food security and production of specialty oils and niche crops. The Company's chief operating decision-maker does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company's consolidated operating results. As of December 31, 2019, and December 31, 2018, less than 10% of the Company's combined total assets were located outside of the United States. During the year ended December 31, 2019 and December 31, 2018, the reported net income (loss) from the Company's foreign subsidiaries was less than 10% of the combined net income (loss) of the consolidated Company.

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation. Repairs and maintenance are charged to operating expense as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the assets once they are placed in service as follows:



Asset Description		Estimated Useful Life (years)
Equipment		3
Furniture and fixtures		5
Software		3
Leasehold improvements		Shorter of useful life or term of lease

The Company records incentive payments received from its landlords as a lease incentive obligation and amortizes these amounts as reductions to lease expense over the lease term.

Impairment of Long-Lived Assets

Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Accounting guidance further requires that companies recognize an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows and measure an impairment loss as the difference between the carrying amount and fair value of the asset.

Grant Revenue

The Company's source of continuing revenue is from its government research grants in which it serves as either the primary contractor or as a subcontractor. These grants are considered an ongoing major and central operation of the Company's business. Revenue is earned as research expenses related to the grants are incurred. Revenue earned on government grants, but not yet invoiced as of the balance sheet date, are recorded as unbilled receivables in the accompanying consolidated balance sheets for the years ended December 31, 2019 and December 31, 2018. Funds received from government grants in advance of work being performed, if any, are recorded as deferred revenue until earned.

Research and Development

All costs associated with internal research and development are expensed as incurred. Research and development expenses include, among others, direct costs for salaries, employee benefits, subcontractors, product trials, facility related expenses, depreciation, and stock-based compensation. Costs incurred in connection with government research grants are recorded as research and development expenses.

General and Administrative Expenses

The Company's general and administrative expense includes costs for salaries, employee benefits, facilities expenses, consulting and professional service fees, travel expenses, depreciation expenses and office related expenses incurred to support the administrative operations of the Company.

Intellectual Property Costs

The Company includes all costs associated with the prosecution and maintenance of patents within general and administrative expenses in the consolidated statement of operations.

Stock-Based Compensation

All share-based payments to employees, members of the Board of Directors and non-employees are recognized within operating expense based on the straight-line recognition of their grant date fair value over the period during which the recipient is required to provide service in exchange for the award. See Note 10 for a description of the types of stock-based awards granted, the compensation expense related to such awards and detail of equity-based awards outstanding.

Basic and Diluted Net Loss per Share

Basic net income (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted-average number of common shares outstanding. Diluted net loss per share is computed by dividing net income available to common shareholders by the weighted-average number of dilutive common shares outstanding during the period. Diluted shares outstanding is calculated by adding to the weighted shares outstanding any potential (unissued) shares of common stock from outstanding stock options and warrants based on the treasury stock method, as well as weighted shares outstanding of any potential (unissued) shares of common stock from restricted stock units. In periods when a net loss is reported, such as the Company's fiscal years ending December 31, 2019 and 2018, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect in the calculation of loss per share; meaning the loss per share would be reduced. Therefore, in periods when a loss is reported, there is no difference in basic and dilutive loss per share. Common stock equivalents include stock options, restricted stock awards, convertible preferred stock and warrants.

The Company follows the two-class method when computing net loss per share, when it has issued shares that meet the definition of participating securities. The two-class method determines net income per share for each class of common and participating securities according to dividends declared or accumulated and participating rights in undistributed earnings. The two-class method requires income available to common stockholders to be allocated between common and participating securities based on their respective rights to receive dividends. In periods of net loss, a participating security that does not have a contractual obligation to share in the loss is not allocated a portion of the net loss when determining loss per share under the two-class method. During November 2019, the Company completed an offering of its securities that included Series A Convertible Preferred Stock and Series B Convertible Preferred Stock meeting the definition of participating securities (See Note 9). However, due to the Company's net loss during the year ended December 31, 2019, no allocation of the net loss was allocated to the preferred shares as the holders of the preferred shares do not have a contractual obligation to fund losses and loss per share has been computed and presented based on the loss being fully assigned to the Company's weighted average outstanding common shares during the year. There were no amounts allocated to participating securities during the year ended December 31, 2018, as the Company had no outstanding securities that met the definition of participating securities.

The number of shares of potentially dilutive common stock presented on a weighted average basis, related to options, restricted stock units, convertible preferred stock and warrants (prior to consideration of the treasury stock method) that were excluded from the calculation of dilutive shares since the inclusion of such shares would be anti-dilutive for the years ended December 31, 2019 and 2018, respectively, are shown below:



	Year Ended December 31,
	2019	2018
Options	54,430	32,359
Restricted stock awards	42	214
Series A Convertible Preferred Stock	18,420	—
Series B Convertible Preferred Stock	82,705	—
Warrants	180,467	243,327
Total	336,064	275,900

Income Taxes

The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company's tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is provided to reduce the deferred tax asset to a level which, more likely than not, will be realized.

The Company accounts for uncertain tax positions using a "more-likely-than-not" threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors that include, but are not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The provision for income taxes includes the effects of any resulting tax reserves or unrecognized tax benefits that are considered appropriate as well as the related net interest and penalties, if any. The Company evaluates uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions.

See Note 12 for further discussion of income taxes. The Company had no amounts recorded for any unrecognized tax benefits as of December 31, 2019 and 2018.

Recent Accounting Standards Changes

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies that the Company adopts as of the specified effective date.

In February 2016, the FASB issued ASU No. 2016-02, which requires lessees to recognize most leases on their balance sheet as right-of-use assets and lease liabilities. In July 2018, the FASB issued ASU No. 2018-10, "Codification Improvements to Topic 842, Leases" ("ASU 2018-10"), which provided narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU No. 2018-11, "Leases (Topic 842 - Targeted Improvements)" ("ASU 2018-11"), which addressed implementation issues related to the new lease standard. The new guidance was effective for annual reporting periods beginning after December 15, 2018 and interim periods within those fiscal years. Under the new standard, disclosures are required to enable users of financial statements to better assess the amount, timing, and uncertainty of cash flows arising from leases. Topic 842 required filers to adopt the new standard using a modified retrospective approach under either of two transition methods; (1) to apply the new lease requirements at the beginning of the earliest period presented, or (2) to apply the new lease requirements at the effective date. The Company adopted the new standard on January 1, 2019 and elected to adjust its 2018 and 2017 financial statements in order to make them comparable to its 2019 financial statements. Adoption of Topic 842 had a material impact on the Company's previously reported 2018 and 2017 financial statements. See Note 11.

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The ASU is the result of a joint project by the FASB and the International Accounting Standards Board ("IASB") to clarify the principles for recognizing revenue and to develop a common revenue standard for GAAP and International Financial Reporting Standards ("IFRS") that would: remove inconsistencies and weaknesses in the treatment of this area between GAAP and IFRS, provide a more robust framework for addressing revenue issues, improve comparability of revenue recognition practices across entities, jurisdictions, industries, and capital markets, improve disclosure requirements and resulting financial statements, and simplify the presentation of financial statements. The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the new standard effective January 1, 2018 using the modified retrospective method and determined that its grant revenue, which is its sole source of revenue, does not fall within the guidance of the new standard. The Company will review future customer revenue agreements against the guidance provided by ASU No. 2014-09 to ensure that revenue is recorded appropriately.

New pronouncements that are not yet effective but may impact the Company's financial statements in the future are described below.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB has subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The Company is evaluating the potential impact of the standard on its consolidated financial position, results of operations and related disclosures.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. This standard modifies certain disclosure requirements on fair value measurements and will become effective for the Company on January 1, 2020. The Company is evaluating the potential impact of the standard on its consolidated financial position and results of operations and related disclosures.

In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606. This standard makes targeted improvements for collaborative arrangements as follows:

•

Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, Revenue from Contracts with Customers, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;


•	Adds unit-of-account guidance to ASC 808, Collaborative Arrangements, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and


•	Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.

This standard will become effective for the Company on January 1, 2020; however, early adoption is permitted. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings, as of January 1, 2019. The Company is currently evaluating the potential impact that this standard may have on its consolidated financial position, results of operations and related disclosures.

Investments

12 Months Ended

Dec. 31, 2019

Investments, Debt and Equity Securities [Abstract]

Investments

INVESTMENTS

The Company's investments consist of the following:



	Accumulated Cost at December 31, 2019		Unrealized				Market Value at December 31, 2019
	Accumulated Cost at December 31, 2019		Gain		(Loss)		Market Value at December 31, 2019
Short-term investments
Government securities	$	5,700	$	—	$	—	$	5,700
Total	$	5,700	$	—	$	—	$	5,700



	Accumulated Cost at December 31, 2018		Unrealized				Market Value at December 31, 2018
	Accumulated Cost at December 31, 2018		Gain		(Loss)		Market Value at December 31, 2018
Short-term investments
Government securities	$	2,746	$	—	$	—	$	2,746
Total	$	2,746	$	—	$	—	$	2,746

Fair Value Measurements

12 Months Ended

Dec. 31, 2019

Fair Value Disclosures [Abstract]

Fair Value Measurements

The Company has certain financial assets recorded at fair value which have been classified as Level 1 and Level 2 within the fair value hierarchy as described in the accounting standards for fair value measurements. In addition, during November 2019 the Company issued Series A Warrants and Series B Warrants in its concurrent securities offerings, that are considered free standing financial instruments that are legally detachable and separately exercisable from the common and preferred stock issued in the two offerings (see Note 9). The Company determined that all of the Series A Warrants and Series B Warrants should be classified as a warrant liability in accordance with ASC 480, Distinguishing Liabilities from Equity, and recognized at their inception date fair value due to the insufficiency of common shares available to permit their exercise. The warrant liability meets Level 3 classification criteria for classification within the fair value hierarchy. Fair value is the price that would be received from the sale of an asset or the price paid to transfer a liability in an orderly transaction between independent market participants at the measurement date. Fair values determined by Level 1 inputs utilize observable data such as quoted prices in active markets for identical instruments. Fair values determined by Level 2 inputs utilize data points other than quoted prices in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its own assumptions. The fair value hierarchy level is determined by the lowest level of significant input.

The Company’s financial assets classified as Level 2 at December 31, 2019 and December 31, 2018 were initially valued at the transaction price and subsequently valued utilizing third-party pricing services. Because the Company’s investment portfolio may include securities that do not always trade on a daily basis, the pricing services use many observable market inputs to determine value including reportable trades, benchmark yields and benchmarking of like securities. The Company validates the prices provided by the third-party pricing services by reviewing their pricing methods and obtaining market values from other pricing sources. After completing the validation procedures, the Company did not adjust or override any fair value measurements provided by these pricing services as of December 31, 2019 and December 31, 2018.

The fair values of the Series A Warrants and Series B Warrants were determined using the Black-Scholes valuation model. The warrants issued in the concurrent public and private offerings possess similar terms, with the exception of the expiration dates between the Series A Warrants and Series B Warrants. The expected volatility and the risk free discount rate used in the Black-Scholes model were determined based on the Company's historical market price published on the Nasdaq Capital Markets and from published U.S. Treasury yield curves, respectively, for a period matched to the contractual term of each warrant series. The resulting aggregate issuance date fair value on the warrant issuance date was determined to be $24,518. The fair value of the warrant liability at December 31, 2019 was determined to be $14,977, resulting in a recognized gain of $9,541 from the change in fair value that is shown within other income (expense) in the Company's consolidated statement of operations for the year ended December 31, 2019.



	Series A Warrants		Series B Warrants
	At December 31, 2019	At Inception	At December 31, 2019	At Inception
Fair market of common stock (per share)	$6.86	$10.82	$6.86	$10.82
Expected term (years)	2.3	2.5	7.3	7.5
Risk free rate	1.62%	1.59%	1.83%	1.73%
Volatility	127%	127%	115%	115%

The tables below present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2019 and December 31, 2018 and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value.



	Fair value measurements at reporting date using
	Quoted prices in active markets for identical assets		Significant other observable inputs		Significant unobservable inputs		Balance as of
Description	(Level 1)		(Level 2)		(Level 3)		December 31, 2019
Assets
Cash equivalents:
Money market funds	$	2,622	$	—	$	—	$	2,622
U.S. government and agency securities	—		1,750		—		1,750
Short-term investments:
U.S. government and agency securities	—		5,700		—		5,700
Total assets	$	2,622	$	7,450	$	—	$	10,072

Liabilities
Warrant liability	$	—	$	—	$	14,977	$	14,977
Total liabilities	$	—	$	—	$	14,977	$	14,977



	Fair value measurements at reporting date using
	Quoted prices in active markets for identical assets		Significant other observable inputs		Significant unobservable inputs		Balance as of
Description	(Level 1)		(Level 2)		(Level 3)		December 31, 2018
Assets
Cash equivalents:
Money market funds	$	2,663	$	—	$	—	$	2,663
Short-term investments:
U.S. government agency securities	—		2,746		—		2,746
Total assets	$	2,663	$	2,746	$	—	$	5,409

There were no transfers of financial assets or liabilities between category levels for the years ended December 31, 2019 and December 31, 2018.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Property and Equipment, Net

12 Months Ended

Dec. 31, 2019

Property, Plant and Equipment [Abstract]

Property and Equipment, Net

Property and equipment consist of the following:



	Year ended December 31,
	2019			2018
Equipment	$	852		$	907
Furniture and fixtures	119			119
Leasehold improvements	1,748			1,749
Software	53			72
Total property and equipment, at cost	2,772			2,847
Less: accumulated depreciation	(1,529		)	(1,462		)
Property and equipment, net	$	1,243		$	1,385

Depreciation expense for the years ended December 31, 2019 and December 31, 2018, was $203 and $196, respectively.

Accrued Expenses

12 Months Ended

Dec. 31, 2019

Payables and Accruals [Abstract]

Accrued Expenses

Accrued expenses consist of the following:



	Year ended December 31,
	2019		2018
Employee compensation and benefits	$	669	$	98
Leased facilities	51		50
Professional services	327		234
Other	279		298
Total accrued expenses	$	1,326	$	680

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Contractual Commitments In connection with the wind down of its biopolymer operations during 2016, the Company ceased pilot production of biopolymer material and reached agreements with the owner-operators of its biopolymer production facilities regarding the early termination of their services. The Company made the final payments of $489 against these early contract termination obligations during 2018. Litigation From time to time, the Company may be subject to legal proceedings and claims in the ordinary course of business. The Company is not currently aware of any such proceedings or claims that it believes will have, individually or in the aggregate, a material adverse effect on the business, financial condition or the results of operations. Guarantees As of December 31, 2019, and December 31, 2018, the Company did not have significant liabilities recorded for guarantees. The Company enters into indemnification provisions under various agreements with other companies in the ordinary course of business, typically with business partners, contractors, and customers. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of its activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date Yield10 Bioscience has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these agreements is minimal. Accordingly, the Company has no liabilities recorded for these agreements as of December 31, 2019 and December 31, 2018.

License Agreements	12 Months Ended
License Agreements	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
License Agreements	License Agreements In October 2019, the Company granted a non-exclusive license to J. R. Simplot ("Simplot"), to evaluate three of the Company's novel traits in potato. Under the agreement, Simplot plans to conduct research with the yield traits C3003, C3004 and C4001 within its research and development program as a strategy to improve crop performance and sustainability. In studies performed by the Company in greenhouse or field tests, these traits have shown a range of promising activities such as good agronomic performance, increased photosynthesis, increased seed yield, and/or increased biomass production. In August 2019, the Company expanded its 2017 non-exclusive research license with the Crop Science Division of Bayer AG (formerly Monsanto Company) ("Bayer"), for soybean crop research to include a new discovery related to its C3004 yield trait gene. Under the original 2017 license, Bayer has the non-exclusive right to begin work with C3003 in its soybean program as a strategy to improve seed yield. Bayer may also conduct research with the Company's C3004 yield trait, a trait accessible through genome editing, in combination with C3003 to evaluate the effectiveness of the combination in improving seed yield in soybean. In September 2018, the Company granted a non-exclusive license to Forage Genetics International, LLC ("Forage Genetics"), a subsidiary of Land O'Lakes, Inc., to evaluate five of the Company's novel traits in forage sorghum. The traits included in the research license include C3003 as well as four traits from the Company's GRAIN platform, C4001, C4002, C4003 and C4029. The C4000 series traits have been shown to significantly increase photosynthesis and biomass in research conducted by the Company. The key objective of the licensing agreement is to provide Forage Genetics with novel traits to test alone and/or in any combination in sorghum that may lead to the identification of new yield traits for potential future licensing from the Company for development and commercial deployment. None of these research arrangements provide significant licensing revenue to the Company while the third parties perform trait evaluations.

Capital Stock and Warrants

12 Months Ended

Dec. 31, 2019

Equity [Abstract]

Capital Stock and Warrants

Common Stock

Reverse Stock Split

On January 15, 2020, the Company completed a 1-for-40 reverse stock split ("reverse stock split") of its common stock by filing a certificate of amendment (the "Charter Amendment") with the State of Delaware to amend its certificate of incorporation. The ratio for the reverse stock split was determined by the Company's board of directors following approval by stockholders at the Company's special meeting held on January 9, 2020. The reverse stock split had the effect of increasing the Company's common shares available for issuance by reducing issued and outstanding common shares by a divisible factor of 40 while its authorized shares remained at its current 60 million. Proportional adjustments were made to the Company's outstanding stock options and to the number of shares issued and issuable under the Company's equity compensation plans.

November 2019 Concurrent Securities Offerings

On November 19, 2019, the Company closed on concurrent securities offerings, receiving combined gross cash proceeds of $11,500, before issuance costs of $1,254. The offerings included a public offering and private placement.

The public portion of the offering included sales of Class A Units or Class B Units as follows:

•

405,750 Class A Units priced at a public offering price of $8.00 per unit, with each unit consisting of one share of common stock, par value $0.01 per share, a Series A Warrant to purchase one share of common stock at an exercise price of $8.00 per share, expiring two and one-half-years from the closing date of the offering, and a Series B Warrant to purchase one share of common stock at an exercise price of $8.00 per share, expiring seven and one-half-years from the closing date of the offering. The 405,750 Class A Units sold include the full exercise of the underwriter's over-allotment option of 93,750 Class A Units.

•

2,504 Class B Units, priced at a public offering price of $1,000 per unit, with each unit consisting of one share of Series A Convertible Preferred Stock, par value $0.01 per share, convertible at any time at the holder's option into 125 shares of common stock, par value $0.01 per share, Series A Warrants to purchase 125 shares of common stock at an exercise price of $8.00 per share, expiring two and one-half-years from the closing date of the offering, and Series B Warrants to purchase 125 shares of common stock at an exercise price of $8.00 per share, expiring seven and one-half-years from the closing date of the offering. The Series A Convertible Preferred Stock is convertible into shares of common stock at any time at a price of $8.00 per share. As of December 31, 2019, 1,708 of the Series A Convertible Preferred Stock had converted to 213,500 shares of the Company's common stock.


•	Gross proceeds from the sale of Class A Units and Class B Units totaled $5,750.

In the concurrent private placement, certain existing shareholders purchased the following securities:

•

5,750 Units, priced at $1,000 per unit, each unit consisting of one share of the Company's Series B Convertible Preferred Stock, par value $0.01, Series A Warrants to purchase 125 shares of common stock at an exercise price of $8.00 per share, expiring two and one-half-years from the closing date of the offering, and Series B Warrants to purchase 125 shares of common stock at an exercise price of $8.00 per share, expiring seven and one-half-years from the closing date of the offering.

•

At issuance, the Series B Convertible Preferred Stock had various superior rights to the Company's other securities, including the Series A Convertible Preferred Stock sold under the public portion of the concurrent offerings. Upon issuance, the Series B Convertible Preferred Stock was contingently redeemable for cash at the election of the holders if the Charter Amendment to effect a reverse stock split did not occur within twelve months of issuance. The Series B Convertible Preferred Stock also had cumulative quarterly dividend rights, payable starting March 31, 2020, pursuant to which the Series B Convertible Preferred stockholders were entitled to receive a dividend initially equal to 2 percent of stated value, plus all accrued and unpaid dividends. The dividends were payable in additional shares of Series B Convertible Preferred Stock and the dividend rate increased 2 percent quarterly as long as the Series B Convertible Preferred Stock remained outstanding. In the event of a liquidation of the Company, the Series B Convertible Preferred stockholders would be paid the greater of the stated value of the shares plus accrued dividends to the point of liquidation prior to payment to junior securities holders, including common stock and the amount payable on the number of shares of common stock the Series B Convertible Preferred Stock holders would be entitled to on an as-if converted basis.


•	Gross proceeds from the private placement also totaled $5,750.

As of the November 19, 2019 closing date of the two offerings, the Company did not have sufficient authorized and available shares of common stock to permit conversion of the Series B Convertible Preferred Stock sold in the private placement or to permit the exercise of the 2,875,000 combined Series A Warrants and Series B Warrants issued under both the public and the private offerings. Under the terms of the offerings, the Series B Convertible Preferred Shares and the Series A Warrants and Series B Warrants were not convertible or exercisable until more shares of common stock became available for issuance through the Company's filing of the Charter Amendment for the reverse stock split. Upon the filing of the Charter Amendment on January 15, 2020, the Series B Convertible Preferred Stock sold in the private placement automatically converted into 718,750 shares of common stock and the Series A Warrants and Series B Warrants issued under both offerings became eligible for exercise.

The accounting for the concurrent securities offerings is highly complex and required significant analysis and judgment in the application of the appropriate accounting guidance. The Company determined that the Series A Convertible Preferred Stock qualified for presentation as permanent equity on the Company's balance sheet as of December 31, 2019. Upon review of the Series B Convertible Preferred Stock, the Company determined that the contingent redemption rights of the Series B Convertible Preferred stockholders are outside the control of the Company and result in the classification of the Series B Convertible Preferred Stock as temporary equity in the Company's balance sheet at December 31, 2019.

The Company determined that the Series A Warrants and Series B Warrants are free standing financial instruments that are legally detachable and separately exercisable from the common and preferred stock issued in the concurrent offerings. The Company determined that all of the warrants should be classified as non-current warrant liabilities recognized at their inception date fair value due to the insufficiency of common shares available to permit their exercise. The fair value of the Series A Warrants and Series B Warrants was determined by the Company using the Black-Scholes valuation model. The computation of expected volatility and the risk-free discount rate were determined based on the Company's historical market price published on the Nasdaq Capital Markets and from published U.S. Treasury yield curves, respectively, for a period matched to the contractual term of each warrant series. The resulting aggregate issuance date fair value on the warrant issuance date was determined to be $24,518.



	Series A Warrants	Series B Warrants
Expected term (years)	2.5	7.5
Risk free rate	1.59%	1.73%
Volatility	127%	115%

The proceeds of the public and private offerings were first allocated to the warrants based on their full fair value. As the proceeds from each of the offerings were less than the fair value of their respective warrant liability, the warrants were recorded at their full fair value and the difference between the fair value and the proceeds of $13,018 was recorded to other income (expense) in the Company's consolidated statement of operations for the year ended December 31, 2019. No allocation of residual offering proceeds remained to be allocated to the common and preferred shares sold in the offerings.

The fair value of the warrant liabilities was subsequently re-measured at December 31, 2019 resulting in the recognition of a gain of $9,541 within other income (expense) in the consolidated statement of operations for the year then ended. The significant reduction in valuation was primarily the result of the decline in the market price of the Company's stock during the period. The other Black-Scholes inputs did not change appreciably from those used for the initial valuation. Upon the filing of the Charter Amendment in January 2020, the warrants will qualify for equity classification and will be reclassified from warrant liability to additional paid-in capital.

As a result of the proceeds of the combined offerings being allocated solely to the liability classified warrants, all of the offering costs of $1,254 were assigned to the warrants and then immediately expensed to other income (expense) in the consolidated statement of operations for the year ended December 31, 2019.

March 2019 Registered Direct Offering

On March 18, 2019, the Company completed a registered direct offering of its common stock. Proceeds from the transaction were $2,932 before issuance costs of $349. Investors participating in the transaction purchased a total of 60,541 shares of common stock at a price of $48.40 per share.

Increase in Authorized Shares of Common Stock

On May 23, 2018, the Company held its 2018 Annual Meeting, at which stockholders approved an amendment to the Certificate of Incorporation to increase from 40,000,000 shares to 60,000,000 shares the aggregate number of shares of common stock that are authorized to be issued. As a result of this vote, on May 23, 2018, the Company filed a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware to increase the number of authorized shares. Also, at the Annual Meeting, stockholders approved the adoption of the Company's 2018 Stock Plan. The 2018 Stock Plan reserves for issuance 32,500 shares of the Company's common stock for grants of incentive stock options, nonqualified stock options, stock grants and stock-based awards. Shares available under the 2018 Stock Plan were increased on the first day of January 2019 and 2020 in an amount equal to 5% of the outstanding shares of common stock on the day prior to the increase in each respective year or such smaller number of shares of common stock as determined by the board of directors.

Preferred Stock

The Company's certificate of incorporation, as amended and restated, authorizes it to issue up to 5,000,000 shares of $0.01 par value preferred stock.

Description of Series A Convertible Preferred Stock

The November 2019 concurrent offerings of the Company's securities included the issuance of 2,504 shares of Series A Convertible Preferred Stock. Each Series A Convertible Preferred Share is convertible into 125 shares of common stock at a conversion price of $8.00 per share, subject to adjustments as a result of stock dividends and stock splits. Material provisions of the Series A Convertible Preferred stock include the following:


•	The Series A Convertible Preferred Stock is not redeemable.


•	Holders of the Series A Convertible Preferred Stock may convert their preferred shares to common stock at any time. Subject to certain conditions, the Company can force a conversion based on certain market price and trading volume criteria.


•	Conversion of the Series A Convertible Preferred Stock is prohibited if, as a result of a conversion, the holder, together with its affiliates, would beneficially own a number of shares of common stock in excess of 4.99% (or at the election of the purchaser prior to the date of issuance, 9.99%) of the shares of the Company's common stock then outstanding after giving effect to such exercise.


•	Holders of the Series A Convertible Preferred Stock have no voting rights. However, Series A Convertible Preferred stockholders have certain protective voting rights that are designed to prevent adverse changes to their ownership rights without their approval.


•	In the event of a liquidation, the holders of Series A Convertible Preferred Shares are entitled to participate on an as-converted-to-common stock basis with holders of common stock in any distribution of assets of the Company to the holders of the common stock.


•	Holders of Series A Convertible Preferred Stock are entitled to receive dividends equal to (on an as-if-converted basis) and in the same form and manner as dividends paid on shares of the Company's common stock.

During the year ended December 31, 2019, 1,708 shares of the Series A Convertible Preferred Stock have been converted to 213,500 shares of common stock.

Description of Series B Convertible Preferred Stock

The November 2019 concurrent offerings of the Company's securities included the issuance of 5,750 shares of Series B Convertible Preferred Stock. Each share of Series B Convertible Preferred Stock is convertible into 125 shares of common stock at a conversion price of $8.00 per share, subject to adjustments as a result of stock dividends and stock splits. Material provisions of the Series B Convertible Preferred stock include the following:


•	On, or after the twelve-month anniversary date of issuance, holders of Series B Convertible Preferred Stock may elect to have the Company redeem all or a portion of their Series B Convertible Preferred Stock at a price per share equal to the stated valued of the shares plus all accrued and unpaid regular dividends thereon to the date of redemption notice.


•	Subject to certain conditions, the Company can force a conversion based on certain market price and trading volume criteria.


•	The Series B Convertible Preferred Stock was not convertible into common stock until shareholders approved the reverse stock split and the Company filed the Charter Amendment. The Charter Amendment was filed on January 15, 2020. Upon the effectiveness of the reverse stock split, the Series B Convertible Preferred Stock automatically converted to common stock.

•

Holders of the Series B Convertible Preferred Stock have no voting rights. However, Series B Convertible Preferred stockholders have certain protective voting rights that are designed to prevent adverse changes to their ownership rights without their approval. The Series B Convertible Preferred stockholders also have a right to approve specified corporate transactions that could result in a material change in the Company's business or the issuance of securities that are more senior to the Series B Convertible Preferred Stock.

•

Holders of Series B Convertible Preferred Stock have a cumulative quarterly dividend right, payable starting March 31, 2020, pursuant to which they are entitled to receive a dividend equal initially to (i) 2 percent of the stated value of the Series B Convertible Preferred Stock plus (ii) all accrued and unpaid dividends. The dividends are payable in additional shares of Series B Convertible Preferred Stock. The dividend rate increases by 2 percent on each quarterly dividend payment date for as long as the Series B Convertible Preferred Stock remains outstanding.


•	In the event of a liquidation, the holders of Series B Convertible Preferred Stock have a liquidation preference that stipulates they would be paid $1,000 per share of Series B Convertible Preferred Stock plus the amount of the accrued dividends to the point of liquidation, prior to any payment to holders of junior securities, including common stock.

The Series B Convertible Preferred Stock automatically converted to 718,750 shares of common stock on January 15, 2020, upon the Company's filing of a Charter Amendment as a result of shareholder approval for the reverse stock split.

When converted, the shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock are restored to the status of authorized but unissued shares of preferred stock, subject to reissuance by the board of directors.

Warrants

The following table summarizes information with regard to outstanding warrants to purchase common stock as of December 31, 2019:



Issuance	Number of Common Shares Issuable Upon Exercise of Outstanding Warrants	Exercise Price		Balance Sheet Classification	Expiration Date
November 2019 Public Offering - Series A	718,750	$	8.00	Liability	May 19, 2022
November 2019 Public Offering - Series B	718,750	$	8.00	Liability	May 19, 2027
November 2019 Private Placement - Series A	718,750	$	8.00	Liability	May 19, 2022
November 2019 Private Placement - Series B	718,750	$	8.00	Liability	May 19, 2027
December 2017 Public Offering - Series A	160,975	$	90.00	Equity	December 21, 2022
July 2017 Registered Direct Offering	14,270	$	201.60	Equity	January 7, 2024
Consultant	750	$	116.00	Equity	September 11, 2024
Total	3,050,995

After December 31, 2019, and through March 20, 2020, Yield10 received a further $1,638 in cash from the exercise of 204,796 warrants issued in the November 2019 offering. During 2018 a total of 1,378 Series B warrants from the Company's December 2017 public offering were exercised resulting in the issuance of 1,378 shares of common stock and the Company's receipt of $124 in cash proceeds. On September 21, 2018, the remaining unexercised Series B warrants from the December 2017 public offering expired in accordance with their terms.

Reserved Shares

The following common stock shares were reserved for future issuance upon exercise of stock options, release of Restricted Stock Units ("RSUs"), conversion of outstanding Series A Convertible Preferred Stock and conversion of outstanding warrants:



	December 31, 2019	December 31, 2018
Stock Options	62,065	43,633
RSUs	—	171
Series A Convertible Preferred Stock - November 2019 Public Offering	99,500	—
Warrants	175,995	185,827
Total number of common shares reserved for future issuance	337,560	229,631

As of the December 31, 2019, the Company did not have sufficient authorized and available shares of common stock to permit conversion of the 718,750 Series B Convertible Preferred Stock sold in the November 2019 private placement or to permit the exercise of the 2,875,000 combined Series A Warrants and Series B Warrants issued in the concurrent public and private offerings. Shares of common stock became available for issuance through the Company's filing of a Charter Amendment for the reverse stock split on January 15, 2020. The Series B Convertible Preferred Stock and the Series A Warrants and Series B Warrants have therefore been excluded from the table of reserved shares shown above.

Stock-Based Compensation

12 Months Ended

Dec. 31, 2019

Share-based Payment Arrangement [Abstract]

Stock-Based Compensation

Stock Option Plans

The Company adopted a stock plan in 2006 (the "2006 Plan"), which provided for the granting of incentive stock options, nonqualified stock options, stock appreciation rights, deferred stock awards, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights. In October 2014, the 2006 Plan was terminated, and the Company adopted a new plan (the "2014 Plan"). No further grants or awards were subsequently made under the 2006 Plan. A total of 3,662 options were awarded from the 2006 Plan and as of December 31, 2019, 509 of these options remain outstanding and eligible for future exercise.

The 2014 Plan provides for the granting of incentive stock options, nonqualified stock options, stock appreciation rights, deferred stock awards, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights. In May 2018, the 2014 Plan was terminated, and the Company adopted a new 2018 Stock Option and Incentive Plan (the "2018 Stock Plan"). A total of 16,896 options have been awarded from the 2014 Plan and as of December 31, 2019, 16,699 of these options remain outstanding and eligible for future exercise. A total of 3,619 restricted stock awards have been awarded from the 2014 Plan and as of December 31, 2019, none of these restricted stock awards are unvested and outstanding. No further stock awards may be issued from the 2014 Plan.

The 2018 Stock Plan reserves for issuance 32,500 shares of the Company's common stock for grants of incentive stock options, nonqualified stock options, stock grants and stock-based awards. Shares available under the 2018 Stock Plan may be increased on the first day of January 2019 and 2020 in an amount equal to 5% of the outstanding shares of common stock on the day prior to the increase in each respective year or such smaller number of shares of common stock as determined by the Board of Directors. The Company's Board of Directors approved the addition of 12,532 and 46,672 shares, respectively, to the 2018 Stock Plan which represented 5% of the outstanding shares of common stock on December 31, 2019 and December 31, 2018. As of December 31, 2019, a total of 44,884 options have been awarded from the 2018 Stock Plan, and as of that date, 44,378 options remain outstanding.

Expense Information for Stock Awards

The Company recognized stock-based compensation expense, related to employee stock awards, including awards to non-employees and members of the Board of Directors, of $656 and $1,181 for the years ended December 31, 2019 and 2018, respectively. At December 31, 2019, there was approximately $1,225 of stock-based compensation expense related to unvested awards not yet recognized which is expected to be recognized over a weighted average period of 2.87 years.

Stock Options

Options granted under the 2006 Plan, 2014 Plan and 2018 Stock Plan generally vest ratably over periods of one to four years from the date of hire for new employees, or date of award for existing employees, or date of commencement of services with the Company for non-employees, and generally expire ten years from the date of issuance. The Company's policy is to issue new shares upon the exercise of stock options.

A summary of the activity related to the shares of common stock covered by outstanding options is as follows:



	Number of Shares		Weighted Average Exercise Price		Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Balance at December 31, 2018	43,633		$	254.00
Granted	18,923		35.31
Exercised	—		—
Forfeited	(444	)	54.30
Expired	(47	)	13,202.22
Balance at December 31, 2019	62,065		178.95		8.13	$	—
Vested and expected to vest at December 31, 2019	62,065		178.95		8.13	$	—
Exercisable at December 31, 2019	31,927		300.03		7.40	—

The weighted average grant date fair value per share of options granted during fiscal years 2019 and 2018, was $30.77, and $53.04, respectively. No options were exercised during 2019 and 2018, and therefore the intrinsic value for exercised options during the two years was not applicable. The weighted average remaining contractual term for options outstanding as of December 31, 2019 was 8.13 years.

For the years ended December 31, 2019, and 2018, the Company determined the fair value of stock options using the Black-Scholes option pricing model with the following assumptions for option grants, respectively:



	Year Ended December 31,
	2019	2018
Expected dividend yield	—	—
Risk-free rate	1.7% - 2.5%	2.6% - 3.1%
Expected option term (in years)	6.0 - 10.0	5.5 - 5.9
Volatility	107% - 124%	107% - 110%

The Company determined its volatility assumption based on actual market price fluctuations experienced during its trading history. The risk-free interest rate used for each grant is equal to the U.S. Treasury yield curve in effect at the time of grant for instruments with a term similar to the expected life of the related option. The expected term of the options is based upon evaluation of historical and expected future exercise behavior.

The stock price volatility and expected terms utilized in the calculation involve management's best estimates at that time, both of which impact the fair value of the option calculated under the Black-Scholes methodology and, ultimately, the expense that will be recognized over the life of the option. The accounting standard for stock-based compensation requires that the Company recognize compensation expense for only the portion of options that vest. The Company recognizes stock option forfeitures resulting from award terminations in the period in which the forfeiture occurs.

Restricted Stock Units ("RSUs")

The Company records stock compensation expense for RSUs on a straight-line basis over their vesting period based on each RSU's award date market value. The Company did not award any RSUs during the years ended December 31, 2019 and December 31, 2018.

The Company pays minimum required income tax withholding associated with RSUs for its employees. As the RSUs vest, the Company will withhold a number of shares with an aggregate fair market value equal to the minimum tax withholding amount (unless the employee makes other arrangements for payment of the tax withholding) from the common stock issuable at the vest date. During the years ended December 31, 2019 and December 31, 2018, the Company withheld vested shares with a fair value of $4 and $6 to pay for minimum tax withholding associated with RSU vesting.

A summary of RSU activity for the year ended December 31, 2019 is as follows:



	Number of RSUs		Weighted Average Remaining Contractual Life (years)
Outstanding at December 31, 2018	171
Awarded	—
Released	(171	)
Forfeited	—
Outstanding at December 31, 2019	—		—

Weighted average remaining recognition period (years)	—

Leases

12 Months Ended

Dec. 31, 2019

Leases [Abstract]

LEASES

New Lease Accounting

Topic 842 became effective for annual reporting periods beginning after December 15, 2018. The Company adopted Topic 842 on January 1, 2019 and elected to apply the new lease accounting requirements to the earliest period presented in its comparative financial statements, using the modified retrospective approach. The guidance also required additional financial statement disclosures to enable users of financial statements to better assess the amount, timing, and uncertainty of cash flows arising from leases. Topic 842 replaced the previous lease accounting and reporting guidance of ASC Topic 840, Leases, ("ASC Topic 840") and required lessees to reflect a right-of-use asset and a lease liability on their balance sheet for leases with terms of more than twelve months.

Application of Topic 842 to the accompanying financial statements for 2019 and 2018 resulted in it reporting right-of-use assets of $3,141 and $4,766 and lease liabilities of $4,221 and $6,465 for real estate and equipment leases as of December 31, 2019 and December 31, 2018, respectively. The Company also eliminated $1,005 in lease incentive obligations from its balance sheet as of December 31, 2018, as a result of the discontinuation of the previous guidance under ASC Topic 840. The impact of the application of the new pronouncement to the Company's statement of operations for the years ended December 31, 2019 and December 31, 2018 was immaterial.

Under Topic 842, leases are classified as either operating or finance leases, with classification based on criteria similar to previous lease accounting guidance, but without the explicit quantitative determining factors used to establish a lease as either a capital or an operating lease. The Company reviewed its 2019 and 2018 leases falling within the scope of Topic 842 and determined that all of these leases met the criteria for classification as operating leases.

Lease liabilities are recorded as of their commencement date and are calculated as the present value of the remaining lease payments, using the interest rate implicit in the lease, or if that rate is not readily determinable, using the lessee's incremental borrowing rate. Right-of-use assets are equal to the lease liability with adjustments made, as necessary, for lease prepayments, lease accruals, initial direct costs, lessor lease incentives and any lease impairments that may be present. Topic 842 further requires that lease expense for operating leases be calculated on a straight-line basis and reported as a single operating expense within income from operations.

Topic 842 provides a number of transitional practical expedients designed to assist lessees with initial implementation. The Company made the following elections in applying Topic 842.


•	Short-term lease exception. Active leases as of January 1, 2018, and new leases entered into thereafter with terms of twelve months or less were and will be excluded from accounting under Topic 842.

•

Package of practical expedients. These expedients, which must be elected in their entirety, permit a company to continue its historical accounting during the transition period for contractual arrangements containing embedded leases in lieu of performing a re-evaluation of the agreements in order to separate lease and non-lease components. The package of expedients also permits a company to maintain its previous accounting classification for transitional leases as either operating or finance leases without reassessment under the new guidance. Lastly, the package of practical expedients does not require reassessment and capitalization of initial direct costs incurred to establish a lease.

In applying the guidance of Topic 842 to the years ended December 31, 2019 and December 31, 2018, the Company did not elect the available hindsight expedient with respect to the determination of lease terms used in the calculation of lease liabilities and right-of-use assets by considering the actual outcome of lease renewals.

In November 2019, the Company entered into a lease modification with the landlord for its headquarters located in Woburn, Massachusetts, as described further below. As a result of returning 7,409 square feet of space to the landlord for the remaining seven-year lease term, the Company remeasured and reduced its associated right-of-use asset and lease liability by $1,011 and $1,401, respectively and recorded a charge to lease expense of $390.

Maturity Analysis of Lease Liabilities

At December 31, 2019, the Company's lease liabilities will mature as follows:



Year ended December 31,	Undiscounted Cash Flows
2020	$	884
2021	704
2022	726
2023	749
2024	771
Thereafter	1,540
Total undiscounted future lease payments	5,374
Discount	(1,153		)
Total lease liabilities	$	4,221
Short-term lease liabilities	$	602
Long-term lease liabilities	$	3,619

At December 31, 2019, real estate and equipment leases represent approximately 99% and 1%, of the Company's lease liabilities, respectively.

Quantitative Disclosure of Lease Costs



	Year ended December 31,
	2019			2018
Lease cost:
Operating lease cost	$	640		$	1,319
Short-term lease cost	569			480
Sublease income	(539		)	(474		)
Total lease cost, net	$	670		$	1,325

Operating lease cost of $640 is shown net of a reduction of $390 related to the Company's modification to its Woburn, Massachusetts lease described above.



Other information as of:	December 31, 2019	December 31, 2018
Weighted-average remaining lease term (years)	6.7	7.4
Weighted-average discount rate	7.24%	6.75%

Real Estate Leases

During 2016, the Company entered into a lease agreement for its headquarters, pursuant to which the Company leased approximately 29,622 square feet of office and research and development space located at 19 Presidential Way, Woburn, Massachusetts. The lease began on June 1, 2016 and will end on November 30, 2026. The lease agreement does not include any options for the early termination or the extension of the lease. The Company provided the landlord with a security deposit in the form of a letter of credit in the amount of $307. Pursuant to the lease, the Company will also pay certain taxes and operating costs associated with the premises throughout the term of the lease. During the buildout of the rented space, the landlord paid $889 for tenant improvements to the facility and an additional $444 for tenant improvements that result in increased rental payments by the Company. Upon the adoption of Topic 842, these improvements were recorded as a reduction in the valuation of the right-of-use asset.

In November 2019, the Company entered into a modification to the Woburn lease in which Yield10 permanently returned 7,409 square feet of underutilized space to the landlord for the seven-year duration of the lease. In exchange for returning the space, the landlord agreed to fund modifications and upgrades to the remaining office space retained by the Company. The modifications were completed in February 2020 and after that point the Company has no further financial obligations for the vacated space and lease rental charges, including utility, maintenance and real estate tax charges, were proportionally reduced. The security deposit was also proportionally reduced to $229.

In October 2016, the Company entered into a sublease agreement with a subsidiary of CJ CheilJedang Corporation ("CJ") with respect to CJ's sublease of 9,874 square feet of its leased facility located in Woburn, Massachusetts. The sublease space was determined to be in excess of the Company's needs. The CJ sublease is unaffected by the Company's recent lease modification with the landlord and remains coterminous with the Company's master lease. CJ will pay pro rata rent and operating expenses equal to the amounts payable to the landlord by the Company, as adjusted from time to time in accordance with the terms of the master lease. Future CJ sublease payments have not been presented as an offset to total undiscounted future lease payments of $5,374 shown in the lease maturity analysis table above. CJ provided the Company with a security deposit of $103 in the form of an irrevocable letter of credit.

The Company also leases approximately 13,702 square feet of office and laboratory space at 650 Suffolk Street, Lowell, Massachusetts. The lease for this facility, as amended, expires in May 2020. During July 2018, the Company discontinued further use of the Lowell space, and as a result, the Company recorded a non-cash lease exit charge of $255 for the facility in accordance with ASC Topic 420-10, Exit or Disposal Obligations. The exit charge was recorded as an increase in the Company's lease expense and a reduction to the associated right-of-use asset. The Company will continue to make monthly rental payments for the Lowell facility through its expiration in May 2020. The Company does not anticipate incurring significant charges in returning this space to the landlord.

The Company's wholly-owned subsidiary, Metabolix Oilseeds, Inc. ("MOI"), located in Saskatoon, Saskatchewan, Canada, leases approximately 7,000 square feet of office, laboratory and greenhouse space located within Innovation Place at 410 Downey Road and within the research facility of National Research Council Canada located at 110 Gymnasium Place. None of the leases contain renewal or early termination options. MOI's leases for these facilities expire on various dates through September 30, 2020.

Income Taxes

12 Months Ended

Dec. 31, 2019

Income Tax Disclosure [Abstract]

Income Taxes

Income Taxes and Deferred Tax Assets and Liabilities

The components of loss from operations before provision for income taxes consist of the following:



	Year Ended December 31,
	2019			2018
Domestic	$	(13,394	)	$	(12,288	)
Foreign	184			3,103
Net loss from operations before income tax benefit	$	(13,210	)	$	(9,185	)

The components of the income tax benefit consisted of the following for the years ended December 31, 2019 and 2018:



	Year Ended December 31,
	2019			2018
Current Tax Benefit:
Federal	$	—		$	—
State	—			—
Foreign	—			—
Total current	—			—

Deferred Tax Benefit:
Federal	—			—
State	—			—
Foreign	(254		)	—
Total deferred	(254		)	—
Total tax provision (benefit)	$	(254	)	$	—

Significant components of the Company's deferred tax assets are as follows:



	Year Ended December 31,
	2019			2018
Deferred Tax Assets:
Net operating loss carryforward	$	25,799		$	24,261
Capitalization of research and development expense	1,162			1,385
Credit carryforwards	2,332			2,664
Capital loss carryover	646			—
Stock compensation	915			966
Lease liability	1,141			—
Other temporary differences	303			695
Total deferred tax assets.	32,298			29,971
Valuation allowance	(30,953		)	(29,672		)
Net deferred tax assets	1,345			299
Deferred Tax Liabilities:
Depreciation	(246		)	(299		)
Right-of-use asset	(845		)	—
Net deferred taxes	$	254		$	—

Tax Rate

The items accounting for the difference between the income tax benefit computed at the federal statutory rate of 21% and the provision for income taxes were as follows:



	Year Ended December 31,
	2019		2018
Federal income tax at statutory federal rate	21.0	%	21.0	%
State taxes	2.0	%	8.0	%
Permanent differences	(0.4	)%	(0.1	)%
Tax credits	0.6	%	3.1	%
Canada credit audit adjustment	(2.6	)%	0.0	%
Foreign rate differential	(0.1	)%	0.0	%
Non-deductible equity transactions	(7.5	)%	0.0	%
Stock compensation	(0.9	)%	(3.6	)%
Other	(0.7	)%	0.6	%
Change in valuation allowance	(9.5	)%	(25.2	)%
German subsidiary dissolution	0.0	%	(3.8	)%
Total	1.9	%	0.0	%

Tax Attributes

At December 31, 2019, the Company had U.S. net operating loss carryforwards (NOLs) for federal and state income tax purposes of approximately $95,626 and $90,461, respectively. Included in the $95,626 of federal net operating losses are losses of $17,817 that will carry forward indefinitely. The remaining federal net operating losses of $77,809 will begin to expire in 2033. The Company's state net operating loss carryforwards will begin to expire on various dates through 2039. The Company also had available research and development and investment tax credits for federal and state income tax purposes of approximately $1,404 and $860, respectively. These federal and state credits will begin to expire on various dates through 2039. In Canada, the Company has cumulative research tax credits totaling $254 that will begin to expire on various dates through 2035.

Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are comprised principally of net operating loss carryforwards and research and development credits. Under the applicable accounting standards, management has considered the Company's history of losses and concluded that it is more likely than not that the Company will not recognize the benefits of U.S. federal and state deferred tax assets. Accordingly, a full valuation allowance has been established against the U.S. deferred tax assets. During 2019 the Company reduced the amount of credits available based upon the conclusion of a tax audit in Canada. As a result, management re-assessed the Company's reduced deferred tax assets and its recent profit history and concluded that it is more likely than not that the Company will recognize the benefit of all the remaining Canadian deferred tax assets. As such, an income tax benefit to reverse the valuation allowance previously established in Canada has been recorded during the fourth quarter of 2019.

Utilization of the net operating loss and research and development credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes may limit the amount of net operating loss and research and development credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. The Company completed an evaluation of its ownership changes through December 31, 2015 and determined that an ownership change occurred on August 22, 2014 in connection with an equity offering. As a consequence of this ownership change, the Company's NOLs, tax credit carryforwards and other tax deductions allocable to the tax periods preceding the ownership change became subject to limitation under Section 382. The Company has reduced its associated deferred tax assets accordingly. The Company has not yet completed an evaluation of ownership changes for the years 2016 through 2019. To the extent an ownership change occurs in the future, the net operating loss, credit carryforwards and other deferred tax assets may be subject to further limitations.

Other

During the year ended December 31, 2018, the Company dissolved its wholly-owned German subsidiary, Metabolix GmbH, that has been inactive since 2014. As a result of this decision, in 2018 the Company wrote off the German deferred tax assets and related full valuation allowance resulting in no impact to the tax provision. The majority of the assets were net operating loss carryforwards.

The tax years 2016 through 2019 remain open to examination by major taxing jurisdictions to which the Company is subject, which are primarily in the U.S. The statute of limitations for net operating losses utilized in future years will remain open beginning in the year of utilization.

The Company's policy is to record estimated interest and penalties related to uncertain tax positions as income tax expense. As of December 31, 2019 and 2018, the Company had no accrued interest or penalties recorded related to uncertain tax positions.

No additional provision has been made for U.S. income taxes related to the undistributed earnings of the wholly-owned subsidiaries of Yield10 Bioscience, Inc. or for unrecognized deferred tax liabilities for temporary differences related to investments in subsidiaries as the amounts are not significant. As such, earnings are expected to be permanently reinvested, the investments are essentially permanent in duration, or the Company has concluded that no additional tax liability will arise as a result of the distribution of such earnings. A liability could arise if amounts are distributed by such subsidiaries or if such subsidiaries are ultimately disposed. It is not practical to estimate the additional income taxes related to permanently reinvested earnings or the basis differences related to investment in subsidiaries. Unremitted earnings at December 31, 2019 and December 31, 2018 approximated $778 and $593, respectively.

Employee Benefits	12 Months Ended
Employee Benefits	Dec. 31, 2019
Retirement Benefits [Abstract]
Employee Benefits	Employee Benefits The Company maintains a 401(k) savings plan in which substantially all of its regular U.S. employees are eligible to participate. Participants may contribute up to 60% of their annual compensation to the plan, subject to eligibility requirements and annual IRS limitations. The Company's plan provides for a matching contribution in common stock of up to 4.5% of a participant's total compensation dependent upon the level of participant contributions made during the plan year. Pursuant to this plan, the Company issued 2,885, and 1,638 shares of common stock during the years ended December 31, 2019, and December 31, 2018, respectively, and recorded $98, and $102, respectively, of related expense. Company contributions are fully vested upon issuance.

U.S. Department of Energy Grants	12 Months Ended
U.S. Department of Energy Grants	Dec. 31, 2019
Research and Development Arrangement with Federal Government [Abstract]
U.S. Department of Energy Grants	U.S. Department of Energy Grants On April 17, 2018 the Company entered into a sub-award with Michigan State University ("MSU") to support a Department of Energy funded grant entitled "A Systems Approach to Increasing Carbon Flux to Seed Oil." The Company's participation under this grant commenced on September 15, 2017 and as of December 31, 2019, the first three years of the sub-award totaling $1,698 have been authorized. The Company anticipates that additional two option years will be awarded annually to Yield10 through September 14, 2022 for total sub-award funding of $2,957, provided the U.S. Congress continues to appropriate funds for the program, the Company is able to make progress towards meeting grant objectives and it remains in compliance with other terms and conditions of the sub-award. During the years ended December 31, 2019 and December 31, 2018, the Company recognized $806 and $419, respectively, in revenue related to this sub-award. In 2015, the Company entered into a multi-year $1,997 grant agreement entitled, Production of High Oil, Transgene Free Camelina Sativa Plants through Genome Editing, with the U.S. Department of Energy for the development of Camelina sativa feedstock. The Company used the funds to perform research to increase oil content and/or seed yield to maximize oil yields per acre. The Company recognized revenue from the grant over the term of the agreement as it incurred related research and development costs and it met its prorated cost-sharing obligation of approximately $500. During the years ended December 31, 2019 and December 31, 2018, the Company recognized $0 and $137, respectively, in revenue related to this grant. The grant ended September 30, 2018 and all revenue under the grant has been recognized.

Geographic Information

12 Months Ended

Dec. 31, 2019

Segment Reporting [Abstract]

Geographic Information

The geographic distribution of the Company's revenues and long-lived assets from continuing operations is summarized as follows:



	U.S.		Canada		Eliminations			Total
Year Ended December 31, 2019
Net revenues to unaffiliated customers	$	806	$	—	$	—		$	806
Inter-geographic revenues	—		1,883		(1,883		)	—
Net revenues	$	806	$	1,883	$	(1,883	)	$	806
Identifiable long-lived assets	$	1,186	$	57	$	—		$	1,243
Year Ended December 31, 2018
Net revenues to unaffiliated customers	$	556	$	—	$	—		$	556
Inter-geographic revenues	—		1,418		(1,418		)	—
Net revenues	$	556	$	1,418	$	(1,418	)	$	556
Identifiable long-lived assets	$	1,372	$	13	$	—		$	1,385

Foreign revenue is based on the country in which the Company's subsidiary that earned the revenue is domiciled. During 2019, grant revenue earned from the Company's Michigan State University sub-award totaled $806, or 100% of the Company's total revenue.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Principles of Consolidation

Use of Estimates

Cash and Cash Equivalents

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid investments purchased with an original maturity date of ninety days or less at the date of purchase to be cash equivalents.

Restricted Cash

Amounts included in restricted cash represent those required to be set aside by contractual agreement.

Investments

Foreign Currency Translation

Comprehensive Income (Loss)

Concentration of Credit Risk

Fair Value Measurements

Segment Information

Property and Equipment



Asset Description		Estimated Useful Life (years)
Equipment		3
Furniture and fixtures		5
Software		3
Leasehold improvements		Shorter of useful life or term of lease

The Company records incentive payments received from its landlords as a lease incentive obligation and amortizes these amounts as reductions to lease expense over the lease term.

Impairment of Long-Lived Assets

Grant Revenue

Research and Development

General, and Administrative Expenses

General and Administrative Expenses

Intellectual Property Costs

The Company includes all costs associated with the prosecution and maintenance of patents within general and administrative expenses in the consolidated statement of operations.

Stock-Based Compensation

Basic and Diluted Net Loss per Share

Income Taxes

See Note 12 for further discussion of income taxes. The Company had no amounts recorded for any unrecognized tax benefits as of December 31, 2019 and 2018.

Recent Accounting Standards Changes

New pronouncements that are not yet effective but may impact the Company's financial statements in the future are described below.

•


•	Adds unit-of-account guidance to ASC 808, Collaborative Arrangements, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and


•	Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Reconciliation of cash, cash equivalents and restricted cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's condensed consolidated balance sheets included herein:



	December 31, 2019		December 31, 2018
Cash and cash equivalents	$	5,417	$	3,023
Restricted cash	332		332
Total cash, cash equivalents and restricted cash	$	5,749	$	3,355

Schedule of estimated useful life of assets used to compute depreciation using the straight-line method

Depreciation is computed using the straight-line method over the estimated useful lives of the assets once they are placed in service as follows:



Asset Description		Estimated Useful Life (years)
Equipment		3
Furniture and fixtures		5
Software		3
Leasehold improvements		Shorter of useful life or term of lease

Property and equipment consist of the following:



	Year ended December 31,
	2019			2018
Equipment	$	852		$	907
Furniture and fixtures	119			119
Leasehold improvements	1,748			1,749
Software	53			72
Total property and equipment, at cost	2,772			2,847
Less: accumulated depreciation	(1,529		)	(1,462		)
Property and equipment, net	$	1,243		$	1,385

Schedule of shares used to calculate diluted earnings per share



	Year Ended December 31,
	2019	2018
Options	54,430	32,359
Restricted stock awards	42	214
Series A Convertible Preferred Stock	18,420	—
Series B Convertible Preferred Stock	82,705	—
Warrants	180,467	243,327
Total	336,064	275,900

Investments (Tables)

12 Months Ended

Dec. 31, 2019

Investments, Debt and Equity Securities [Abstract]

Schedule of investment holdings

The Company's investments consist of the following:



	Accumulated Cost at December 31, 2019		Unrealized				Market Value at December 31, 2019
	Accumulated Cost at December 31, 2019		Gain		(Loss)		Market Value at December 31, 2019
Short-term investments
Government securities	$	5,700	$	—	$	—	$	5,700
Total	$	5,700	$	—	$	—	$	5,700



	Accumulated Cost at December 31, 2018		Unrealized				Market Value at December 31, 2018
	Accumulated Cost at December 31, 2018		Gain		(Loss)		Market Value at December 31, 2018
Short-term investments
Government securities	$	2,746	$	—	$	—	$	2,746
Total	$	2,746	$	—	$	—	$	2,746

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2019

Fair Value Disclosures [Abstract]

Fair value measurement inputs



	Series A Warrants		Series B Warrants
	At December 31, 2019	At Inception	At December 31, 2019	At Inception
Fair market of common stock (per share)	$6.86	$10.82	$6.86	$10.82
Expected term (years)	2.3	2.5	7.3	7.5
Risk free rate	1.62%	1.59%	1.83%	1.73%
Volatility	127%	127%	115%	115%



	Series A Warrants	Series B Warrants
Expected term (years)	2.5	7.5
Risk free rate	1.59%	1.73%
Volatility	127%	115%

Assets and liabilities measured at fair value on a recurring basis

s below present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2019 and December 31, 2018 and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value.



	Fair value measurements at reporting date using
	Quoted prices in active markets for identical assets		Significant other observable inputs		Significant unobservable inputs		Balance as of
Description	(Level 1)		(Level 2)		(Level 3)		December 31, 2019
Assets
Cash equivalents:
Money market funds	$	2,622	$	—	$	—	$	2,622
U.S. government and agency securities	—		1,750		—		1,750
Short-term investments:
U.S. government and agency securities	—		5,700		—		5,700
Total assets	$	2,622	$	7,450	$	—	$	10,072

Liabilities
Warrant liability	$	—	$	—	$	14,977	$	14,977
Total liabilities	$	—	$	—	$	14,977	$	14,977



	Fair value measurements at reporting date using
	Quoted prices in active markets for identical assets		Significant other observable inputs		Significant unobservable inputs		Balance as of
Description	(Level 1)		(Level 2)		(Level 3)		December 31, 2018
Assets
Cash equivalents:
Money market funds	$	2,663	$	—	$	—	$	2,663
Short-term investments:
U.S. government agency securities	—		2,746		—		2,746
Total assets	$	2,663	$	2,746	$	—	$	5,409

Property and Equipment, Net (Tables)

12 Months Ended

Dec. 31, 2019

Property, Plant and Equipment [Abstract]

Schedule of components of property and equipment

Depreciation is computed using the straight-line method over the estimated useful lives of the assets once they are placed in service as follows:



Asset Description		Estimated Useful Life (years)
Equipment		3
Furniture and fixtures		5
Software		3
Leasehold improvements		Shorter of useful life or term of lease

Property and equipment consist of the following:



	Year ended December 31,
	2019			2018
Equipment	$	852		$	907
Furniture and fixtures	119			119
Leasehold improvements	1,748			1,749
Software	53			72
Total property and equipment, at cost	2,772			2,847
Less: accumulated depreciation	(1,529		)	(1,462		)
Property and equipment, net	$	1,243		$	1,385

Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2019

Payables and Accruals [Abstract]

Schedule of accrued expenses

Accrued expenses consist of the following:



	Year ended December 31,
	2019		2018
Employee compensation and benefits	$	669	$	98
Leased facilities	51		50
Professional services	327		234
Other	279		298
Total accrued expenses	$	1,326	$	680

Capital Stock and Warrants (Tables)

12 Months Ended

Dec. 31, 2019

Equity [Abstract]

Fair value measurement inputs



	Series A Warrants		Series B Warrants
	At December 31, 2019	At Inception	At December 31, 2019	At Inception
Fair market of common stock (per share)	$6.86	$10.82	$6.86	$10.82
Expected term (years)	2.3	2.5	7.3	7.5
Risk free rate	1.62%	1.59%	1.83%	1.73%
Volatility	127%	127%	115%	115%



	Series A Warrants	Series B Warrants
Expected term (years)	2.5	7.5
Risk free rate	1.59%	1.73%
Volatility	127%	115%

Information with regard to outstanding warrants to purchase common stock

The following table summarizes information with regard to outstanding warrants to purchase common stock as of December 31, 2019:



Issuance	Number of Common Shares Issuable Upon Exercise of Outstanding Warrants	Exercise Price		Balance Sheet Classification	Expiration Date
November 2019 Public Offering - Series A	718,750	$	8.00	Liability	May 19, 2022
November 2019 Public Offering - Series B	718,750	$	8.00	Liability	May 19, 2027
November 2019 Private Placement - Series A	718,750	$	8.00	Liability	May 19, 2022
November 2019 Private Placement - Series B	718,750	$	8.00	Liability	May 19, 2027
December 2017 Public Offering - Series A	160,975	$	90.00	Equity	December 21, 2022
July 2017 Registered Direct Offering	14,270	$	201.60	Equity	January 7, 2024
Consultant	750	$	116.00	Equity	September 11, 2024
Total	3,050,995

Schedule of primary rights of convertible preferred stockholders, and common stock shares reserved for future issuance



	December 31, 2019	December 31, 2018
Stock Options	62,065	43,633
RSUs	—	171
Series A Convertible Preferred Stock - November 2019 Public Offering	99,500	—
Warrants	175,995	185,827
Total number of common shares reserved for future issuance	337,560	229,631

- Definition

Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2019

Share-based Payment Arrangement [Abstract]

Summary of the activity related to the shares of common stock covered by outstanding options under the plans

A summary of the activity related to the shares of common stock covered by outstanding options is as follows:



	Number of Shares		Weighted Average Exercise Price		Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Balance at December 31, 2018	43,633		$	254.00
Granted	18,923		35.31
Exercised	—		—
Forfeited	(444	)	54.30
Expired	(47	)	13,202.22
Balance at December 31, 2019	62,065		178.95		8.13	$	—
Vested and expected to vest at December 31, 2019	62,065		178.95		8.13	$	—
Exercisable at December 31, 2019	31,927		300.03		7.40	—

Schedule of assumptions used in determining fair value of stock options granted using the Black-Scholes option pricing model



	Year Ended December 31,
	2019	2018
Expected dividend yield	—	—
Risk-free rate	1.7% - 2.5%	2.6% - 3.1%
Expected option term (in years)	6.0 - 10.0	5.5 - 5.9
Volatility	107% - 124%	107% - 110%

Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity

A summary of RSU activity for the year ended December 31, 2019 is as follows:



	Number of RSUs		Weighted Average Remaining Contractual Life (years)
Outstanding at December 31, 2018	171
Awarded	—
Released	(171	)
Forfeited	—
Outstanding at December 31, 2019	—		—

Weighted average remaining recognition period (years)	—

Leases (Tables)

12 Months Ended

Dec. 31, 2019

Leases [Abstract]

Maturity analysis of lease liabilities

At December 31, 2019, the Company's lease liabilities will mature as follows:



Year ended December 31,	Undiscounted Cash Flows
2020	$	884
2021	704
2022	726
2023	749
2024	771
Thereafter	1,540
Total undiscounted future lease payments	5,374
Discount	(1,153		)
Total lease liabilities	$	4,221
Short-term lease liabilities	$	602
Long-term lease liabilities	$	3,619

Quantitative disclosure of lease costs

Quantitative Disclosure of Lease Costs



	Year ended December 31,
	2019			2018
Lease cost:
Operating lease cost	$	640		$	1,319
Short-term lease cost	569			480
Sublease income	(539		)	(474		)
Total lease cost, net	$	670		$	1,325

Operating lease cost of $640 is shown net of a reduction of $390 related to the Company's modification to its Woburn, Massachusetts lease described above.



Other information as of:	December 31, 2019	December 31, 2018
Weighted-average remaining lease term (years)	6.7	7.4
Weighted-average discount rate	7.24%	6.75%

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2019

Income Tax Disclosure [Abstract]

Schedule of components of profit (loss) before provision for income taxes

The components of loss from operations before provision for income taxes consist of the following:



	Year Ended December 31,
	2019			2018
Domestic	$	(13,394	)	$	(12,288	)
Foreign	184			3,103
Net loss from operations before income tax benefit	$	(13,210	)	$	(9,185	)

Components of income tax benefit

The components of the income tax benefit consisted of the following for the years ended December 31, 2019 and 2018:



	Year Ended December 31,
	2019			2018
Current Tax Benefit:
Federal	$	—		$	—
State	—			—
Foreign	—			—
Total current	—			—

Deferred Tax Benefit:
Federal	—			—
State	—			—
Foreign	(254		)	—
Total deferred	(254		)	—
Total tax provision (benefit)	$	(254	)	$	—

Schedule of significant components of the Company's net deferred tax asset

Significant components of the Company's deferred tax assets are as follows:



	Year Ended December 31,
	2019			2018
Deferred Tax Assets:
Net operating loss carryforward	$	25,799		$	24,261
Capitalization of research and development expense	1,162			1,385
Credit carryforwards	2,332			2,664
Capital loss carryover	646			—
Stock compensation	915			966
Lease liability	1,141			—
Other temporary differences	303			695
Total deferred tax assets.	32,298			29,971
Valuation allowance	(30,953		)	(29,672		)
Net deferred tax assets	1,345			299
Deferred Tax Liabilities:
Depreciation	(246		)	(299		)
Right-of-use asset	(845		)	—
Net deferred taxes	$	254		$	—

Schedule of items accounting for the difference between the income tax benefit computed at the federal statutory rate and the provision for income taxes

The items accounting for the difference between the income tax benefit computed at the federal statutory rate of 21% and the provision for income taxes were as follows:



	Year Ended December 31,
	2019		2018
Federal income tax at statutory federal rate	21.0	%	21.0	%
State taxes	2.0	%	8.0	%
Permanent differences	(0.4	)%	(0.1	)%
Tax credits	0.6	%	3.1	%
Canada credit audit adjustment	(2.6	)%	0.0	%
Foreign rate differential	(0.1	)%	0.0	%
Non-deductible equity transactions	(7.5	)%	0.0	%
Stock compensation	(0.9	)%	(3.6	)%
Other	(0.7	)%	0.6	%
Change in valuation allowance	(9.5	)%	(25.2	)%
German subsidiary dissolution	0.0	%	(3.8	)%
Total	1.9	%	0.0	%

Geographic Information (Tables)

12 Months Ended

Dec. 31, 2019

Segment Reporting [Abstract]

Schedule of the geographic distribution of revenues and long-lived assets from continuing operations

The geographic distribution of the Company's revenues and long-lived assets from continuing operations is summarized as follows:



	U.S.		Canada		Eliminations			Total
Year Ended December 31, 2019
Net revenues to unaffiliated customers	$	806	$	—	$	—		$	806
Inter-geographic revenues	—		1,883		(1,883		)	—
Net revenues	$	806	$	1,883	$	(1,883	)	$	806
Identifiable long-lived assets	$	1,186	$	57	$	—		$	1,243
Year Ended December 31, 2018
Net revenues to unaffiliated customers	$	556	$	—	$	—		$	556
Inter-geographic revenues	—		1,418		(1,418		)	—
Net revenues	$	556	$	1,418	$	(1,418	)	$	556
Identifiable long-lived assets	$	1,372	$	13	$	—		$	1,385

Nature of Business and Basis of Presentation (Details) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended
	Nov. 19, 2019	Mar. 31, 2019	Mar. 20, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Unrestricted cash, cash equivalents and short-term investments				$ 11,117
Registered direct offering
Subsidiary, Sale of Stock [Line Items]
Amount received from offering of common stock, net of issuance costs		$ 2,582
Public and private offerings
Subsidiary, Sale of Stock [Line Items]
Amount received from offering of common stock, net of issuance costs	$ 10,246
Warrants \| Subsequent Event
Subsidiary, Sale of Stock [Line Items]
Proceeds from securities offerings, net of issuance costs			$ 1,638
Issuance of stock (in shares)			204,796

Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Cash and cash equivalents	$ 5,417	$ 3,023
Restricted cash	332	332
Total cash, cash equivalents and restricted cash	$ 5,749	$ 3,355	$ 14,804

Summary of Significant Accounting Policies - Estimated Useful Lives (Details)	12 Months Ended
	Dec. 31, 2019
Equipment
Property and Equipment
Estimated Useful Life	3 years
Furniture and fixtures
Property and Equipment
Estimated Useful Life	5 years
Software
Property and Equipment
Estimated Useful Life	3 years

Summary of Significant Accounting Policies - Antidilutive Common Stock Excluded From Calculation of Dilutive Shares (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	336,064	275,900
Options
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	54,430	32,359
Restricted stock awards
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	42	214
Warrants
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	180,467	243,327
Series A Convertible Preferred Stock \| Convertible Preferred Stock
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	18,420	0
Series B Convertible Preferred Stock \| Convertible Preferred Stock
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	82,705	0

Summary of Significant Accounting Policies - Narrative (Details)		12 Months Ended
	Jan. 15, 2020	Dec. 31, 2019 USD ($) segment	Dec. 31, 2018 USD ($)
Concentration of credit risk
Restricted cash		$ 332,000	$ 332,000
Long-term investments		0	0
Unbilled receivables, current		$ 92,000
Number of operating segments \| segment		1
Unrecognized tax benefits		$ 0	0
U.S Government Grants
Concentration of credit risk
Unbilled receivables, current		$ 62,000	$ 160,000
Subsequent Event
Concentration of credit risk
Reverse stock split, conversion ratio	0.025

Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Short-term Investments [Abstract]
Accumulated Cost	$ 5,700	$ 2,746
Unrealized Gain	0	0
Unrealized (Loss)	0	0
Market Value	5,700	2,746
Government securities
Short-term Investments [Abstract]
Accumulated Cost	5,700	2,746
Unrealized Gain	0	0
Unrealized (Loss)	0	0
Market Value	$ 5,700	$ 2,746

Fair Value Measurements - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Nov. 19, 2019
Fair Value Disclosures [Abstract]
Warrant liability	$ 14,977	$ 0	$ 24,518
Gain from change in fair value or warrants	$ 9,541	$ 0

Fair Value Measurements - Fair Value Measurement Inputs (Details)	Dec. 31, 2019 $ / shares	Nov. 19, 2019 $ / shares
Series A Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, expected term		2 years 6 months
Series A Warrants \| Fair market value of common stock
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	6.86	10.82
Series A Warrants \| Expected term (years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, expected term	2 years 3 months 19 days	2 years 6 months 2 days
Series A Warrants \| Risk free rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.0162	0.0159
Series A Warrants \| Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	1.27	1.27
Series B Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, expected term		7 years 6 months
Series B Warrants \| Fair market value of common stock
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	6.86	10.82
Series B Warrants \| Expected term (years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, expected term	7 years 3 months 19 days	7 years 6 months 2 days
Series B Warrants \| Risk free rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.0183	0.0173
Series B Warrants \| Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	1.15	1.15

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Nov. 19, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	$ 5,700		$ 2,746
Warrant liability	14,977	$ 24,518	0
U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	5,700		2,746
Fair Value, Measurements, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	10,072		5,409
Warrant liability	14,977
Total liabilities	14,977
Fair Value, Measurements, Recurring \| U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	5,700		2,746
Fair Value, Measurements, Recurring \| Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	2,622		2,663
Fair Value, Measurements, Recurring \| U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	1,750
Fair Value, Measurements, Recurring \| Quoted prices in active markets for identical assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	2,622		2,663
Warrant liability	0
Total liabilities	0
Fair Value, Measurements, Recurring \| Quoted prices in active markets for identical assets (Level 1) \| U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0		0
Fair Value, Measurements, Recurring \| Quoted prices in active markets for identical assets (Level 1) \| Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	2,622		2,663
Fair Value, Measurements, Recurring \| Quoted prices in active markets for identical assets (Level 1) \| U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0
Fair Value, Measurements, Recurring \| Significant other observable inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	7,450		2,746
Warrant liability	0
Total liabilities	0
Fair Value, Measurements, Recurring \| Significant other observable inputs (Level 2) \| U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	5,700		2,746
Fair Value, Measurements, Recurring \| Significant other observable inputs (Level 2) \| Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0		0
Fair Value, Measurements, Recurring \| Significant other observable inputs (Level 2) \| U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	1,750
Fair Value, Measurements, Recurring \| Significant unobservable inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	0		0
Warrant liability	14,977
Total liabilities	14,977
Fair Value, Measurements, Recurring \| Significant unobservable inputs (Level 3) \| U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0		0
Fair Value, Measurements, Recurring \| Significant unobservable inputs (Level 3) \| Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0		$ 0
Fair Value, Measurements, Recurring \| Significant unobservable inputs (Level 3) \| U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 0

Property and Equipment, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Property and equipment, net
Total property and equipment, at cost	$ 2,772	$ 2,847
Less: accumulated depreciation	(1,529)	(1,462)
Property and equipment, net	1,243	1,385
Depreciation	203	196
Equipment
Property and equipment, net
Total property and equipment, at cost	852	907
Furniture and fixtures
Property and equipment, net
Total property and equipment, at cost	119	119
Leasehold improvements
Property and equipment, net
Total property and equipment, at cost	1,748	1,749
Software
Property and equipment, net
Total property and equipment, at cost	$ 53	$ 72

Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Employee compensation and benefits	$ 669	$ 98
Leased facilities	51	50
Professional services	327	234
Other	279	298
Total accrued expenses	$ 1,326	$ 680

Commitments and Contingencies (Details) $ in Thousands	12 Months Ended
Commitments and Contingencies (Details) $ in Thousands	Dec. 31, 2019 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Payments for early contract termination	$ 489

Capital Stock and Warrants - Narrative (Details) $ / shares in Units, $ in Thousands								1 Months Ended	3 Months Ended	12 Months Ended
	Jan. 15, 2020 shares	Jan. 01, 2020	Dec. 31, 2019 USD ($) $ / shares shares	Nov. 19, 2019 USD ($) $ / shares shares	Mar. 18, 2019 USD ($) $ / shares shares	Jan. 01, 2019	Dec. 31, 2018 USD ($) $ / shares shares	Dec. 31, 2017 shares	Mar. 20, 2020 USD ($) shares	Dec. 31, 2019 USD ($) $ / shares shares	Dec. 31, 2018 USD ($) $ / shares shares	May 23, 2018 shares	May 22, 2018 shares
Class of Stock [Line Items]
Proceeds from Issuance of Warrants \| $				$ 13,018
Change in fair value of warrants \| $										$ (9,541)	$ 0
Temporary Equity, Number Of Shares Of Common Stock Issuable For Each Share Upon Conversion				125
Temporary Equity, Conversion Price \| $ / shares				$ 8.00
Temporary Equity, Shares Issued, Price Per Share \| $ / shares				$ 1,000
Number Of Shares Of Convertible Preferred Stock Included In Each Unit Of Temporary Equity				1
Common stock, shares authorized (in shares)			60,000,000				60,000,000			60,000,000	60,000,000	60,000,000	40,000,000
Gross proceeds from transaction \| $				$ 11,500
Increase in shares available for issuance, percent			5.00%			5.00%	5.00%
Temporary Equity, Initial Dividend Rate				2.00%
Temporary Equity, Annual Increase In Dividend Rate				2.00%
Number of securities called by warrants (in shares)			3,050,995	2,875,000						3,050,995
Preferred stock, shares authorized			5,000,000							5,000,000
Preferred stock, par value per share (in dollars per share) \| $ / shares			$ 0.01							$ 0.01
Warrant liability (Note 9) \| $			$ 14,977	$ 24,518			$ 0			$ 14,977	$ 0
Common stock, par value per share (in dollars per share) \| $ / shares			$ 0.01	$ 0.01			$ 0.01			$ 0.01	$ 0.01
Issuance of preferred stock in connection with private offering (in shares)				5,750						5,750
Series B Convertible Preferred Stock, par value per share (in dollars per share) \| $ / shares			$ 0.01	$ 0.01			0.01			$ 0.01	$ 0.01
Common Stock
Class of Stock [Line Items]
Issuance of stock (in shares)										213,500	20,287
Conversion of Stock, Shares Issued, Cumulative			213,500							213,500
Series A Warrants
Class of Stock [Line Items]
Exercise price of warrants (in USD per share) \| $ / shares				$ 8
Warrants, expected term				2 years 6 months
Series B Warrants
Class of Stock [Line Items]
Proceeds from securities offerings, net of issuance costs \| $										$ 124
Exercise price of warrants (in USD per share) \| $ / shares				$ 8
Warrants, expected term				7 years 6 months
Series B Warrants \| Common Stock
Class of Stock [Line Items]
Issuance of stock (in shares)										1,378	1,377
Class A Units
Class of Stock [Line Items]
Number Of Shares Of Common Stock Included In Each Unit				1
Class A Units \| Series A Warrants
Class of Stock [Line Items]
Number of securities called by each warrant or right				1
Class B Units
Class of Stock [Line Items]
Number Of Shares Of Common Stock Included In Each Unit				1
Class B Units \| Series A Warrants
Class of Stock [Line Items]
Number of securities called by each warrant or right				125
Class B Units \| Series B Warrants
Class of Stock [Line Items]
Number of securities called by each warrant or right				125
Series A Convertible Preferred Stock
Class of Stock [Line Items]
Issuance of stock (in shares)								2,504
Convertible Preferred Stock, Number Of Common Shares Issuable For Each Share Of Preferred Stock				125
Preferred Stock Conversions, Conversion Price \| $ / shares				$ 8.00
Preferred Stock, Convertible, Conversion Prohibited, Percentage of Common Stock Owned After Transaction				4.99%
Preferred Stock, Convertible, Conversion Prohibited, Percentage of Common Stock Owned After Transaction, If Elected				9.99%
Preferred stock, par value per share (in dollars per share) \| $ / shares			$ 0.01	$ 0.01			$ 0.01			$ 0.01	$ 0.01
Conversion of Stock, Shares Converted, Cumulative			1,708							1,708
Scenario, Forecast
Class of Stock [Line Items]
Increase in shares available for issuance, percent		5.00%
Risk free rate \| Series A Warrants
Class of Stock [Line Items]
Warrants, measurement input			0.0162	0.0159						0.0162
Risk free rate \| Series B Warrants
Class of Stock [Line Items]
Warrants, measurement input			0.0183	0.0173						0.0183
Volatility \| Series A Warrants
Class of Stock [Line Items]
Warrants, measurement input			1.27	1.27						1.27
Volatility \| Series B Warrants
Class of Stock [Line Items]
Warrants, measurement input			1.15	1.15						1.15
2018 Stock Plan
Class of Stock [Line Items]
Shares reserved for issuance			32,500							32,500		32,500
Subsequent Event
Class of Stock [Line Items]
Reverse stock split, conversion ratio	0.025
Common stock, shares authorized (in shares)	60,000,000
Subsequent Event \| Common Stock
Class of Stock [Line Items]
Conversion of Stock, Shares Issued	718,750
Subsequent Event \| Warrants
Class of Stock [Line Items]
Proceeds from securities offerings, net of issuance costs \| $									$ 1,638
Issuance of stock (in shares)									204,796
Public and private offerings
Class of Stock [Line Items]
Issuance costs \| $				$ 1,254
Public offering
Class of Stock [Line Items]
Gross proceeds from transaction \| $				$ 5,750
Public offering \| Common Stock
Class of Stock [Line Items]
Issuance of stock (in shares)										405,750
Public offering \| Class A Units
Class of Stock [Line Items]
Common stock issued in offering (in shares)				405,750
Common stock price (in dollars per share) \| $ / shares				$ 8
Public offering \| Class B Units
Class of Stock [Line Items]
Common stock issued in offering (in shares)				2,504
Common stock price (in dollars per share) \| $ / shares				$ 1,000
Registered direct offering
Class of Stock [Line Items]
Gross proceeds from transaction \| $				$ 5,750	$ 2,932
Issuance costs \| $					$ 349
Common stock issued in offering (in shares)					60,541
Common stock price (in dollars per share) \| $ / shares					$ 48.40
Registered direct offering \| Common Stock
Class of Stock [Line Items]
Issuance of stock (in shares)										60,541
Over-Allotment Option [Member] \| Class A Units
Class of Stock [Line Items]
Common stock issued in offering (in shares)				93,750

Capital Stock and Warrants - Fair Value Inputs of Warrants (Details)	Dec. 31, 2019	Nov. 19, 2019
Series A Warrants
Class of Warrant or Right [Line Items]
Warrants, expected term		2 years 6 months
Series B Warrants
Class of Warrant or Right [Line Items]
Warrants, expected term		7 years 6 months
Expected term (years) \| Series A Warrants
Class of Warrant or Right [Line Items]
Warrants, expected term	2 years 3 months 19 days	2 years 6 months 2 days
Expected term (years) \| Series B Warrants
Class of Warrant or Right [Line Items]
Warrants, expected term	7 years 3 months 19 days	7 years 6 months 2 days
Risk free rate \| Series A Warrants
Class of Warrant or Right [Line Items]
Warrants, measurement input	0.0162	0.0159
Risk free rate \| Series B Warrants
Class of Warrant or Right [Line Items]
Warrants, measurement input	0.0183	0.0173
Volatility \| Series A Warrants
Class of Warrant or Right [Line Items]
Warrants, measurement input	1.27	1.27
Volatility \| Series B Warrants
Class of Warrant or Right [Line Items]
Warrants, measurement input	1.15	1.15

Capital Stock and Warrants - Schedule Of Warrants Issuance (Details) - $ / shares	Dec. 31, 2019	Nov. 19, 2019
Class of Stock [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)	3,050,995	2,875,000
Warrants - expiration January 2024
Class of Stock [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)	14,270
Exercise Price (in USD per share)	$ 201.6
Warrants - expiration September 2024
Class of Stock [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)	750
Exercise Price (in USD per share)	$ 116
Public offering \| Series A Warrants - expiration May 2022
Class of Stock [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)	718,750
Exercise Price (in USD per share)	$ 8
Public offering \| Series B Warrants - expiration May 2027
Class of Stock [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)	718,750
Exercise Price (in USD per share)	$ 8
Public offering \| Series A Warrants - expiration December 2022
Class of Stock [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)	160,975
Exercise Price (in USD per share)	$ 90
Registered direct offering \| Series A Warrants - expiration May 2022
Class of Stock [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)	718,750
Exercise Price (in USD per share)	$ 8
Registered direct offering \| Series B Warrants - expiration May 2027
Class of Stock [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)	718,750
Exercise Price (in USD per share)	$ 8

Capital Stock and Warrants - Schedule of Common Stock Reserved For Future Issuance (Details) - shares	Dec. 31, 2019	Dec. 31, 2018
Class of Stock [Line Items]
Total number of common shares reserved for future issuance	337,560	229,631
Options
Class of Stock [Line Items]
Total number of common shares reserved for future issuance	62,065	43,633
Restricted Stock Units (RSUs)
Class of Stock [Line Items]
Total number of common shares reserved for future issuance	0	171
Series A Convertible Preferred Stock
Class of Stock [Line Items]
Total number of common shares reserved for future issuance	99,500	0
Warrants
Class of Stock [Line Items]
Total number of common shares reserved for future issuance	175,995	185,827

Stock-Based Compensation - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands					12 Months Ended
	Jan. 01, 2020	Dec. 31, 2019	Jan. 01, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	May 23, 2018
Stock-based compensation
Unvested and outstanding restricted stock (in shares)		0		171	0	171
Increase in shares available for issuance, percent		5.00%	5.00%	5.00%
Additional shares authorized			46,672
Stock-based compensation					$ 656	$ 1,181
RSUs awarded (in shares)					0
Fair value of vested shares withheld for minimum tax withholding					$ 4	$ 6
2018 Stock Plan
Stock-based compensation
Shares reserved for issuance		32,500			32,500		32,500
Stock options
Stock-based compensation
Unvested and outstanding options (in shares)		62,065		43,633	62,065	43,633
Expiration period					10 years
Weighted average grant date fair value of options granted (in dollars per share)					$ 30.77	$ 53.04
Weighted average remaining contractual term for options outstanding					8 years 1 month 17 days
Exercise of common stock options (in shares)					0
Stock options \| Employee and Director
Stock-based compensation
Stock-based compensation expense, net of estimated forfeitures, related to unvested awards not yet recognized		$ 1,225			$ 1,225
Weighted average period over which unrecognized compensation expense is expected to be recognized					2 years 10 months 15 days
Stock options \| Minimum
Stock-based compensation
Vesting period for options granted					1 year
Stock options \| Maximum
Stock-based compensation
Vesting period for options granted					4 years
Stock options \| 2006 Plan
Stock-based compensation
Options awarded to date (in shares)		3,662			3,662
Unvested and outstanding options (in shares)		509			509
Stock options \| 2014 Plan
Stock-based compensation
Options awarded to date (in shares)		16,896			16,896
Unvested and outstanding options (in shares)		16,699			16,699
Stock options \| 2018 Stock Plan
Stock-based compensation
Options awarded to date (in shares)		44,884			44,884
Unvested and outstanding options (in shares)		44,378			44,378
Restricted stock awards \| 2014 Plan
Stock-based compensation
Options awarded to date (in shares)		3,619			3,619
Restricted Stock Units (RSUs)
Stock-based compensation
Fair value of vested shares withheld for minimum tax withholding					$ 4	$ 6
Scenario, Forecast
Stock-based compensation
Increase in shares available for issuance, percent	5.00%
Subsequent Event
Stock-based compensation
Additional shares authorized	12,532

Stock-Based Compensation - Stock Option Activity (Details) - Stock options $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019 USD ($) $ / shares shares
Number of Shares
Balance at the beginning of the period (in shares) \| shares	43,633
Granted (in shares) \| shares	18,923
Exercised (in shares) \| shares	0
Forfeited (in shares) \| shares	(444)
Expired (in shares) \| shares	(47)
Balance at the end of the period (in shares) \| shares	62,065
Vested and expected to vest at the end of the period (in shares) \| shares	62,065
Options exercisable at the end of the period (in shares) \| shares	31,927
Weighted Average Exercise Price
Balance at the beginning of the period (in dollars per share) \| $ / shares	$ 254.00
Granted (in dollars per share) \| $ / shares	35.31
Exercised (in dollars per share) \| $ / shares	0.00
Forfeited (in dollars per share) \| $ / shares	54.30
Expired (in dollars per share) \| $ / shares	13,202.22
Balance at the end of the period (in dollars per share) \| $ / shares	178.95
Vested and expected to vest at the end of the period (in dollars per share) \| $ / shares	178.95
Exercisable at the end of the period (in dollars per share) \| $ / shares	$ 300.03
Remaining Contractual Term
Balance	8 years 1 month 17 days
Vested and expected to vest	8 years 1 month 17 days
Exercisable	7 years 4 months 24 days
Aggregate Intrinsic Value
Balance \| $	$ 0
Vested and expected to vest \| $	0
Exercisable \| $	$ 0

Stock-Based Compensation - Assumptions Used for Fair Value of Stock Options (Details) - Employee and Director - Stock options	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Assumptions used to determine fair value of stock options
Expected dividend yield	0.00%	0.00%
Risk-free rate, minimum	1.70%	2.60%
Risk-free rate, maximum	2.50%	3.10%
Volatility, minimum	107.00%	107.00%
Volatility, maximum	124.00%	110.00%
Minimum
Assumptions used to determine fair value of stock options
Expected option term	6 years	5 years 6 months
Maximum
Assumptions used to determine fair value of stock options
Expected option term	10 years	5 years 10 months 24 days

Stock-Based Compensation - Restricted Stock Units (RSUs) (Details)	12 Months Ended
	Dec. 31, 2019 shares
Number of RSUs
Outstanding at December 31, 2018	171
Awarded	0
Released	(171)
Forfeited	0
Outstanding at December 31, 2019	0

Leases - Narrative (Details) $ in Thousands		1 Months Ended			12 Months Ended
Leases - Narrative (Details) $ in Thousands	Jan. 01, 2019 USD ($)	Nov. 30, 2019 USD ($) ft²	Jul. 31, 2018 USD ($)	Oct. 31, 2016 USD ($) ft²	Dec. 31, 2019 USD ($) ft²	Dec. 31, 2018 USD ($)	Dec. 31, 2016 USD ($) ft²
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Right-of-use assets					$ 3,141	$ 4,766
Lease liabilities					4,221	6,465
Operating lease cost					640	$ 1,319
Undiscounted future lease payments					5,374
19 Presidential Way, Woburn, Massachusetts
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Space returned to landlord (in sqft) \| ft²		7,409
Remaining lease term		7 years
Reduction in right-of-use asset, lease modification		$ 1,011
Reduction in lease liability, lease modification		1,401
Operating lease expense reduction, lease modification		390
Leased area (in sqft) \| ft²							29,622
Security deposit - letter of credit		$ 229					$ 307
Operating leases, landlord reimbursement for lease improvements							889
Operating leases, landlord reimbursement for lease improvements, additional payments							$ 444
Subleased area (in sqft) \| ft²				9,874
Undiscounted future lease payments					$ 5,374
650 Suffolk Street, Lowell, Massachusetts
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Leased area (in sqft) \| ft²					13,702
Non-cash lease exit charge			$ 255
410 Downey Road and 110 Gymnasium Place
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Leased area (in sqft) \| ft²					7,000
Topic 842
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Elimination of lease incentive obligations	$ 1,005
Office buildings and facilities
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percent of lease liabilities					99.00%
Equipment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percent of lease liabilities					1.00%
CJ CheilJedang Corporation \| 19 Presidential Way, Woburn, Massachusetts
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Security deposit - letter of credit				$ 103

Leases - Maturity Analysis of Lease Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Leases [Abstract]
2020	$ 884
2021	704
2022	726
2023	749
2024	771
Thereafter	1,540
Total undiscounted future lease payments	5,374
Discount	(1,153)
Total lease liabilities	4,221	$ 6,465
Short-term lease liabilities	602	844
Long-term lease liabilities	$ 3,619	$ 5,621

Leases - Quantitative Disclosure of Lease Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Lease cost:
Operating lease cost	$ 640	$ 1,319
Short-term lease cost	569	480
Sublease income	(539)	(474)
Total lease cost, net	$ 670	$ 1,325
Other information as of:
Weighted-average remaining lease term	6 years 8 months 15 days	7 years 4 months 24 days
Weighted-average discount rate	7.24%	6.75%

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Components of profit (loss) before provision for income taxes
Domestic	$ (13,394)	$ (12,288)
Foreign	184	3,103
Net loss from operations before income tax benefit	(13,210)	(9,185)
Current Tax Benefit:
Federal	0	0
State	0	0
Foreign	0	0
Total current	0	0
Deferred Tax Benefit:
Federal	0	0
State	0	0
Foreign	(254)	0
Total deferred	(254)	0
Total tax provision (benefit)	(254)	0
Deferred Tax Assets:
Net operating loss carryforward	25,799	24,261
Capitalization of research and development expense	1,162	1,385
Credit carryforwards	2,332	2,664
Capital loss carryover	646	0
Stock compensation	915	966
Lease liability	1,141	0
Other temporary differences	303	695
Total deferred tax assets.	32,298	29,971
Valuation allowance	(30,953)	(29,672)
Net deferred tax assets	1,345	299
Deferred Tax Liabilities:
Depreciation	(246)	(299)
Right-of-use asset	(845)	0
Net deferred taxes	$ 254	$ 0
Difference between income tax benefit computed at the federal statutory rate and the provision for income taxes
Federal income tax at statutory federal rate	21.00%	21.00%
State taxes	2.00%	8.00%
Permanent differences	(0.40%)	(0.10%)
Tax credits	0.60%	3.10%
Canada credit audit adjustment	(2.60%)	0.00%
Foreign rate differential	(0.001)	(0.000)
Non-deductible equity transactions	(7.50%)	0.00%
Stock compensation	(0.90%)	(3.60%)
Other	(0.70%)	0.60%
Change in valuation allowance	(9.50%)	(25.20%)
German subsidiary dissolution	0.00%	(3.80%)
Total	1.90%	0.00%

Income Taxes - Details Textual (Details) - USD ($)	12 Months Ended
Income Taxes - Details Textual (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Income Tax Contingency [Line Items]
Interest and penalties accrued	$ 0	$ 0
Provision for income taxes for undistributed earnings of foreign subsidiaries	0
Undistributed earnings of foreign subsidiaries	778,000	$ 593,000
Internal Revenue Service (IRS)
Income Tax Contingency [Line Items]
Net operating loss carryforwards	95,626,000
Net operating losses not subject to expiration	17,817,000
Net operating losses subject to expiration	77,809,000
State and Local Jurisdiction
Income Tax Contingency [Line Items]
Net operating loss carryforwards	90,461,000
Research Tax Credit Carryforward \| Internal Revenue Service (IRS)
Income Tax Contingency [Line Items]
Tax credit carryforward, amount	1,404,000
Research Tax Credit Carryforward \| State and Local Jurisdiction
Income Tax Contingency [Line Items]
Tax credit carryforward, amount	860,000
Research Tax Credit Carryforward \| Foreign Tax Authority
Income Tax Contingency [Line Items]
Tax credit carryforward, amount	$ 254,000

Employee Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
Employee Benefits (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Retirement Benefits [Abstract]
Maximum contribution by participants under the 401(k) savings plan (as a percent)	60.00%
Employer's matching contribution in common stock as a percentage of a participant's total compensation, percent	4.50%
Common stock issued under the 401(k) savings plan (in shares)	2,885	1,638
Related expense for common stock issued under the 401(k) savings plan	$ 98	$ 102

U.S. Department of Energy Grants (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2015
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues	$ 806	$ 556
Systems Approach to Increasing Carbon Flux to Seed Oil
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Cumulative amount awarded	1,698
Total expected funding	2,957
Production of High Oil, Transgene Free Camelina Sativa Plants through Genome Editing
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Multi-year grant agreement amount			$ 1,997
Prorated cost-sharing obligation amount	500
Grant revenue
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues	806	556
Grant revenue \| Systems Approach to Increasing Carbon Flux to Seed Oil
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues	806	419
Grant revenue \| Production of High Oil, Transgene Free Camelina Sativa Plants through Genome Editing
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues	$ 0	$ 137

Geographic Information (Details) - USD ($) $ in Thousands	12 Months Ended
Geographic Information (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Geographic Information
Net revenues	$ 806	$ 556
Identifiable long-lived assets	1,243	1,385
U.S.
Geographic Information
Net revenues	806	556
Identifiable long-lived assets	1,186	1,372
Canada
Geographic Information
Net revenues	1,883	1,418
Identifiable long-lived assets	57	13
Eliminations
Geographic Information
Net revenues	(1,883)	(1,418)
Inter-geographic revenues \| Canada
Geographic Information
Net revenues	1,883	1,418
Inter-geographic revenues \| Eliminations
Geographic Information
Net revenues	$ (1,883)	$ (1,418)

Geographic Information - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenue earned
Revenues	$ 806	$ 556
Customer Concentration Risk \| Revenues \| US Department of Energy
Revenue earned
Percentage of total revenue	100.00%
Grant revenue
Revenue earned
Revenues	$ 806	556
Grant revenue \| Systems Approach to Increasing Carbon Flux to Seed Oil
Revenue earned
Revenues	$ 806	$ 419